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Abstract 
 
DE NOVO DESIGN AND ENGINEERING OF FUNCTIONAL METAL AND PORPHYRIN-
BINDING PROTEIN DOMAINS 
 
by 
 
Bernard H. Everson 
 
 
Advisor: Professor Ronald L. Koder 
 
 
In this work, I describe an approach to the rational, iterative design and characterization 
of two functional cofactor-binding protein domains. First, a hybrid computational/experimental 
method was developed with the aim of algorithmically generating a suite of porphyrin-binding 
protein sequences with minimal mutual sequence information. This method was explored by 
generating libraries of sequences, which were then expressed and evaluated for function. One 
successful sequence is shown to bind a variety of porphyrin-like cofactors, and exhibits light-
activated electron transfer in mixed hemin:chlorin e6 and hemin:Zn(II)-protoporphyrin IX 
complexes. These results imply that many sophisticated functions such as cofactor binding and 
electron transfer require only a very small number of residue positions in a protein sequence to 
be fixed. 
Net charge and hydrophobic content are important in determining protein solubility and 
stability.1,2 Accordingly, rational modifications were made to the aforementioned design 
procedure in order to improve its overall success rate. The effects of these modifications are 
explored using two ‘next-generation’ sequence libraries, which were separately expressed and 
evaluated. Particular modifications to these design parameters are demonstrated to effectively 
double the purification success rate of the procedure.  
v 
Finally, I describe the redesign of the artificial di-iron protein DF2 into CDM13, a single 
chain di-Manganese four-helix bundle. CDM13 acts as a functional model of natural manganese 
catalase, exhibiting a kcat of 0.08s
-1 under steady-state conditions. The bound manganese 
cofactors have a reduction potential of +805 mV vs NHE, which is too high for efficient 
dismutation of hydrogen peroxide. These results indicate that as a high-potential manganese 
complex, CDM13 may represent a promising first step toward a polypeptide model of the 
Oxygen Evolving Complex of the photosynthetic enzyme Photosystem II. 
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Chapter 1: Introduction 
 
 The development of renewable, environmentally friendly energy sources is one of the 
primary scientific challenges of the 21st century. Sunlight is the most abundant form of energy 
available to the planet, and the rate at which the earth receives solar energy is more than 
sufficient to satisfy worldwide energy consumption for the foreseeable future.3 The utility and 
sustainability of solar energy over traditional fossil fuels is evident, and yet due to the inherent 
limitations on any single solution it is generally accepted that a mix of solar energy technologies 
will be necessary for the efficient capture and storage of this resource in the future.4 
Natural photosynthesis supports all life on earth by converting solar energy to chemical 
energy using a robust and self-assembling molecular mechanism. In this way, photosynthetic 
organisms represent a highly sophisticated and self-replicating approach to the challange of 
extracting useable energy from the sun. Nevertheless, the natural photosynthetic apparatus 
suffers from at least two distinct disadvantages compared to artificial photovoltaic devices: First, 
it is hampered by the need to function inside a living organism.4 And second, it is the result of 
the evolutionary process, which selects for reproductive success over solar energy conversion 
efficiency.5  
 Decades of research have led to a molecule-level understanding of the mechanisms of 
natural photosynthesis.6 In essence, all photosynthetic systems consist of three parts: 1) a light-
harvesting apparatus capable of creating an electronic excitation from one or more absorbed 
photons; 2) a charge separation mechanism capable of shuttling a photoexcited electron from a 
donor molecule to an acceptor molecule; and 3) an active site that creates some form of useable 
chemical energy from the electronic excitation. As a proof of concept, many bio-inspired 
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synthetic systems have been able to recreate individual aspects of the photosynthetic 
mechanism.7 Unfortunately, many of these systems have proven expensive and environmentally 
unsafe to produce.8 In addition, such systems are inevitably difficult to synthesize and not 
scalable for global needs.  
  De novo protein design techniques seek to produce protein sequences from scratch with 
entirely new or radically simplified folds and functions, rather than modifications of wild-type 
structures.9 As a field, de novo protein design has advanced from the creation of structured 
proteins10-12 to the incorporation of small-molecule binding sites13-15 on to the design of fully 
active enzymes capable of novel or radically improved function.16,17 Thus, modern synthetic 
biologists now have at their disposal a toolkit resulting from decades of research into the 
fundamental sequence-structure-function relation in proteins.  
 The goal of this dissertation is to utilize the principles of de novo protein design to 
develop and iteratively refine functional artificial prototypes of two photosynthetic elements. 
With a focus on the radical redesign and optimization of existing biological mechanisms, 
synthetic biology has been recognized as an attractive approach to the problem of adapting the 
natural photosynthetic toolkit to human needs. Accordingly, this work is grounded in the decades 
of research that have been devoted to uncovering and applying the design parameters of a 
functional photosynthetic system.18,19  
Chapters 2 through 4 of this dissertation describe the development and evaluation of a 
novel de novo design technique for reliably generating diverse libraries of stable cofactor-
binding protein domains. Charge separation and electron transfer events between chromophores 
are the central features of the photosynthetic mechanism, and as such these events are highly 
sensitive to the arrangement and spacing of these chromophores.20-22 In this context, the protein 
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backbone plays a crucial role as a scaffold for positioning photoactive cofactors, and any 
polypeptide model of photosynthetic mechanisms must therefore heavily feature a variety of 
such scaffolds. Fortunately, de novo protein design techniques and protein folding principles are 
ideally suited to the creation of protein sequences capable of binding cofactors with nativelike 
structure.  
Chapter 5 of this dissertation describes the re-engineering of an existing de novo 
dimetalloprotein backbone into a functional di-manganese enzyme. In oxygenic photosynthesis, 
the large protein complex Photosystem II (PSII) is responsible for the first steps in the sequence 
of light-driven reactions necessary for catalysis. Within PSII, the Oxygen Evolving Complex 
(OEC) is a tetrameric manganese complex that provides the electrons for all subsequent 
photosynthetic reactions by splitting water (Eq. 1). 
(1)  2H2O ⟶ O2 + 4H
+ + 4e− 
As the only known example of a water oxidation catalyst in biology, the structure and chemical 
function of the OEC has been the subject of detailed study for decades. Accordingly, there have 
been great advances in synthetic molecular models of this system. To date, however, a de novo 
protein subunit capable of water oxidation has yet to be developed. Although the goal of a de 
novo water splitting enzyme has not been achieved in this work, the di-manganese system 
discussed may nevertheless serve as a future engineering platform for such a functional model of 
the OEC.   
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Chapter 2: Pattern-based Protein Design 
 
2.1 Porphyrin-binding Protein Design  
 As early as 1987, amphipathic alpha-helical bundles have been used as a target structural 
motif for de novo designed proteins.23 Part of the utility of this structure is due to its high 
intrinsic ‘designability’ as measured by the number of amino acid sequences with that structure 
as their lowest energy conformation.24 Importantly, the four-helix bundle also features an 
extended hydrophobic core consisting of opposing helical faces. This presents a well-ordered and 
controllable context for the incorporation of small molecule cofactors, and thus chemical 
functionality.9 
One of the primary considerations in developing a functional cofactor or metal-binding 
protein is structural specificity. Since the beginning of the last decade, the technique of ‘binary 
patterning’ has been used with much success to reliably generate alpha helical bundles.25 This 
method involves the incorporation of a repeating seven-residue pattern of nonpolar and polar 
amino acids with high helical propensities, often termed the ‘heptad repeat,’ to drive the 
formation of amphipathic helices. Under appropriate conditions, these helices will tend to 
associate into dimers, trimers, and higher-order structures. Thus, with only consideration for the 
relative hydrophobicity of amino acid types at certain regular intervals, acceptable tertiary 
structure can be achieved. 
2.1.1 Ternary Patterning. Although binary patterning is a conceptually simple and 
useful method, natural proteins do not exclusively exhibit this pattern to yield structure. Chothia 
et al. investigated the sequence-structure relationship in the Immunoglobin Variable Domain 
using a residue classification scheme based on two related properties: 1) the tendency of residues 
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to be found either on the interior or exterior of a folded protein; and 2) the free energy associated 
with the transfer of a particular amino acid between water and an organic solvent.26 This analysis 
suggests that amino acids be divided into three, rather than two categories: hydrophilic, 
hydrophobic, and neutral. Hydrophilic amino acids have a negative nonpolar to polar transfer 
free energy and exhibit a high tendency to appear on the exterior of the protein. Inversely, 
hydrophobic amino acids have a high transfer free energy and a tendency to be found in the 
hydrophobic interior of the protein. In contrast, both the transfer free energy and interior-exterior 
propensity of the neutral amino acids are close to zero, indicating that residues in this group can 
be found with nearly equal likelihood on the surface or in the interior of the folded protein.  
In the same way that polar or nonpolar amino acids are placed at either exterior or core 
positions in a binary patterning scheme, hydrophobic (core), hydrophilic (surface) or neutral 
(interfacial) amino acid types could be arranged in a pattern to yield structure. The approach 
outlined in this work, which seizes upon the high ‘designability’ of four helix bundles, utilizes 
bioinformatically-derived design parameters to explore the space of potentially useful amino acid 
sequences without a substantial loss in structural specificity.  
 
2.2 Optimal Heme Binding Site 
Natural proteins commonly adopt chemical functionality by incorporating one or more 
small molecule cofactors at well-defined active sites. Accordingly and from the beginning, the 
protein design community has focused on engineering cofactor binding sites into de novo protein 
sequences.27,28 In the case of the single-chain alpha helical four-helix bundle motif, an ideal 
porphryn binding site involves bis-histidine ligation between a pair of parallel helices. This 
binding configuration is not only common in wild-type proteins and thus well characterized, but 
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the favorable iron-histidine binding interaction has been shown enforce a native-like bound state 
in previous de novo designed bundles, obviating the need to engineer elaborate complimentary 
hydrophobic interactions in the protein core.29 Fortunately, previous bioinformatic studies have 
yielded useful design parameters for this geometry and permit a maximal likelihood approach to 
the incorporation of cofactors.  
 Negron et al. surveyed all well-resolved, non-redundant structures of porphryn binding 
proteins whose ligating histidine side chains are in alpha helices, and were able to group them 
according to the side-chain angles of the ligating histidine residue.30 The most populous – and 
therefore the lowest energy – of these rotamer configurations is nicknamed ‘T73’ (Figure 1); T73 
is a bis-histidine configuration featuring mean χ1 and χ2 torsion angles of -175° and 73° 
respectively.31 
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Figure 1. Representative histidine residues for each rotamer group, as identified by Negron et al.30  
 
  
Within each rotamer group, all amino acid sequences within two alpha-helical turns (8 
positions) of the ligating residue were aligned to yield frequency tables. By selecting those 
residues that appear at each position with a frequency of at least 25%, a consensus sequence was 
derived for each group. The result of this analysis suggests that only certain fixed residue 
identities and positions must be included in a protein sequence in order to permit porphyrin 
binding (Table 1).  
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Table 1. Rotamer-dependent consensus sequences for each rotamer group.30 Residues appearing with a frequency of 
at least 25% are specified, variable positions are marked as ‘X’, and ligating histidine positions are underlined.  
Name Consensus Sequence 
t73 IIXXXFXXHAXXGIIIF 
m166 AXXACXACHXXLA 
t86        AHXXYXXYF 
m80  LKXLSXFHXX 
 
 
2.3 Amino Acid Probability Distribution 
The value of the analysis in Section 2.1.1 is that it indicates the appropriate residues for 
each solvent exposure category (core, surface and interfacial), and when paired with 
bioinformatic studies of sequence-structure relationships in wild-type proteins, discrete amino 
acid probability distributions for each of these categories can be derived. This allows for the 
systematic implementation of a ternary pattern based design scheme: generation of sequences by 
directly sampling such probability distributions for all the amino acid positions on a given 
protein backbone.  
 Specifically, amino acid probability distributions were assigned for core, surface and 
interfacial amino acid positions using the database-derived helical residue frequencies of Engel 
and Degrado32 with the following modifications: First, to ensure helicity in the resulting 
sequences, all residues with Chou-Fasman helical propensities 33 of less than 0.90 were 
eliminated. Next, since histidine was chosen as the ligating residue at the binding site, it too was 
excluded from the pool of candidate amino acids. Finally, because the eventual design goal is to 
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enable electron transfer events between bound cofactors,34 the electroactive residues tryptophan, 
cysteine, and tyrosine are likewise excluded.  
 Sequences are further simplified by eliminating side chains within solvent exposure 
categories that are found with a frequency of less than 10% in these places: The hydrophobic 
residues isoleucine, leucine, methionine, and valine were eliminated as candidates for placement 
on the surface. Similarly, the hydrophilic residues glutamate, glutamine, lysine, and arginine 
were eliminated as candidates for placement in the core. Core and surface probabilities were then 
normalized for each of the remaining candidate residues within each category so that the sum of 
the probabilities is 1 (see Table 2). 
(2)    piI =100´ 1-
s iB -s
i
E
s jB -s
j
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j=1
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ê
ê
ê
ù
û
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ú
   
 
 Engel and Degrado did not collect side chain probabilities for interfacial residue types. 
These probabilities were instead assigned according to Eq. 2 above, where piI  is the interface 
probability for residue type i, N is the total number of residues under consideration in all 
categories, and s iB  and s
i
E
 are the probabilities given by Engel and DeGrado 32 for residue i at 
typical buried and exposed positions, respectively. In this way, residues with small differences in 
probability between typical buried and solvent-exposed positions are given the greatest 
probability to be assigned to interfacial positions. Those residues with large differences in 
probability between exposed and buried positions (phenylalanine, methionine, arginine, and 
valine) are given interface probabilities of 0 and are not included in the above calculation. The 
result of this analysis is the normalized probability distribution shown in Table 2 below. 
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Table 2. The normalized probability distributions for core, surface, and interface positions of alpha helices. Each 
entry represents the probability (normalized to 100%) that the corresponding residue will appear in the given 
position category.   
Residue Core Probability Surface Probability Interface Probability 
A 15.8 20.6 19.4 
E 0.0 21.3 14.7 
F 13.8 0.0 0.0 
I 17.4 0.0 15.5 
K 0.0 19.5 15.9 
L 19.3 0.0 15.8 
M 20.1 0.0 0.0 
Q 0.0 19.7 18.4 
R 0.0 18.7 0.0 
V 13.4 0.0 0.0 
 
 
2.4 Wire Frame Backbone Design 
In order to utilize the aforementioned amino acid distribution, a sequence of position 
categories (core, surface, interface, fixed) must be generated from an ideal wireframe backbone. 
The first step is to create a four-helix backbone containing two bound cofactors, the cofactor-
binding histidine ligands and a minimal cofactor-packing interface. Starting with four idealized 
3.6 residue/turn alpha helices (Fig 2A), the ProtCad software package was employed to create a 
D2 symmetric 35 all-alanine model helical bundle within the geometric constraints imposed by 
the cofactor binding site: optimal Nε-Nε distances of 4Å 36 between pairs of ligand histidines 
each in the T73 rotamer. 
  
 
 
 
 
 
 
 
 
 
 
 
 11 
Figure 2. Minimalist pathway for protein design. (A) Four idealized, 3.6 residue/turn alpha helices are arranged into 
a straight D2-symmetric bundle. (B) A superhelical twist is applied to the bundle, and inter-helix spacing is adjusted 
with the ProtCad software package. (C) Generic cofactor models are added, along with ligating histidine residues in 
the T73 rotamer configuration, highlighted in red. (D) Consensus residues are added to the backbone, highlighted in 
purple. (E) The remaining positions on each helix are assigned as core (orange), surface (green), or interface (blue) 
positions by inspection. (F) A sequence is generated according to the amino acid probability distributions of Table 
XX. (G) The pattern of positions is shown as a linear sequence where Z = core, U = surface, and X = interface. All 
other positions are specified explicitly. 
 
 
  
 The result of this process is a bundle model with a superhelical pitch of 175Å (Figure 
2B), very close to the value of 171Å found in natural Cytochrome BC1.37 Because no helix-helix 
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side chain packing interactions between pairs of adjacent antiparallel helices were considered in 
this design process, the separation between these pairs of helices was chosen to be 15Å in order 
to accommodate many possible pairs of side chains at interfacial positions. In accordance with 
previous studies on cofactor separation and electron transfer rates,38 pairs of adjacent helices 
were offset from one another such that the smallest edge-to-edge distance between cofactors was 
20Å. 
 Binding sites were then filled with a cofactor model consisting of a disc 1.4 Å thick with 
a diameter corresponding to the largest edge-to-edge distance of the porphyrin moiety of a heme 
molecule, about 9 Å. Cofactor-helix and cofactor-cofactor distances in the holoprotein complex 
were then adjusted with ProtCAD to remove steric clashes. After the placement of the generic 
bound cofactor perpendicular to the ligand histidine Nε-Nε axis, the four side chains on each 
ligating helix which form the optimal packing interface predicted on the basis of the 
bioinformatic analysis of heme-binding helices, were modeled into the binding site.  
 Figure 2D presents an unminimized model in which each of these side chains are placed 
in the lowest energy helical rotamer as predicted by Lovell et al.39 Gratifyingly, these side chains 
and rotamers create a complementary surface for porphyrin ring binding which contacts roughly 
75% of the possible surface area without Van der Waals clashes. As cofactor or substrate binding 
using low-energy side chain conformations has been shown to be a hallmark of tight binding, this 
observation indicates that such a minimalist binding site can form the basis for high cofactor 
affinity. 
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Starting with the model structure shown in Figure 2D, each unassigned side chain was 
assigned to one of three categories – core, surface or interface – by visual inspection of each 
alanine β carbon position and the direction of the Cα-Cβ bond vector. The end result of these 
assignments, with Cβ atoms shown as spheres, is shown in Fig 2E.  
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Chapter 3: First Generation Sequence Libraries 
 
3.1 HPG Library 
3.1.1 Algorithmic Sequence Generation. The normalized amino acid probabilities 
shown in Table XX represent a discrete probability distribution within each solvent exposure 
category (core, surface, or interface). Positions of a given category are assigned by sampling the 
corresponding distribution. Concretely, for the arbitrarily ordered set of residues in a category, a 
cumulant is constructed where is probability of selecting residue i. A random 
number u is generated where  and the index k is found such that < u < . The 
residue at index k in the category is then assigned to the position in question. This procedure is 
repeated for each unassigned position of the corresponding category (Fig 2G) to yield a full 
amino acid sequence for the backbone structure. Figure 2F shows the end result of this process: 
an unminimized backbone structure complete with a fully assigned candidate amino acid 
sequence. 
 In order to determine the efficacy of the aforementioned approach to de novo porphyrin-
binding protein design, a representative library of ten sequences was generated and targeted for 
expression. Specifically, full-length sequences were produced according to the sequence 
generation protocol outlined above, and candidate sequences were then screened for net charge 
using a minimum absolute value of 7 at pH 7. The ten sequences resulting from this design 
process, named HPG1 – HPG10 (HPG for Heme Protein Generic) are shown in Table 
ck = pi
i=1
k
å pi
0 £ u£100 ck-1 ck
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Table 3. The HPG and HPGA protein sequences, and the steps in the purification process that were possible for each sequence. Helical regions are underlined 
and fixed amino acid identities are highlighted in bold for each sequence.  
 
Name Sequence Purification 
Step1 
HPG-1 
QELRRHARKAIKIQEEVIAIMWILLR GGSNSGSGG RALKAHARLAIRVLQIILAIMEEVLQ GGSSTGSGG 
KKLREHAKIAIQIQAIQEELQEFQKR GGSSGGSGG AQLKVHALMAIQIQQLIQAAARMLWE 
E 
HPG-2 
QILAAHAALAIALQAKFIQMFWALAQ GGSNSGSGG KKLARHAKLAIELLEQALAAIEKVQK GGSSTGSGG 
RQLELHAKVAIQIRKLIAKMQELIAE GGSSGGSGG QILRAHAQFAIAIRALIAIIKRVQWI 
E 
HPG-3 
RQLAQHAKLAIKAAEKIEWMMKEIIR GGSNSGSGG ELLQQHAAIAIALMAIMIQIIERMKR GGSSTGSGG 
AILRIHAEMAILVKQLKQKMLEMEAQ GGSSGGSGG ALLRLHAQMAIKFQEFEQAMKRFLWQ 
E,C,P 
HPG-5 
ALLEQHARKAIQIEQKLLQMVWAFIR GGSNSGSGG EELREHARAAIRMFEKVERKMEKIKK GGSSTGSGG 
QQLRIHAQMAIALKALAQLLAEFAER GGSSGGSGG ALLRAHAAIAIELRAVLRKLERVAWI 
E,C 
HPG-6 
QALQEHAKEAIEVIEAAARAIWIFEK GGSNSGSGG AKLEEHAQIAIRMMKQVIQQMEAMEQ GGSSTGSGG 
RALAKHARAAIEMQKMAEEFEELQEK GGSSGGSGG EELELHALFAIIMERAQEIMKEILWL 
NE 
HPG-7 
EALEKHAAAAIALLAIVLQAMWELKA GGSNSGSGG EELERHAEIAIQALRQLLAQFEQMAE GGSSTGSGG 
RILEQHAQVAIQIQEAAELFAAFQQA GGSSGGSGG IALELHAEVAIAIKQFQQEMARMKWE 
NE 
HPG-8 
EILQAHAQAAIEMLKQFLQMFWQLEE GGSNSGSGG EELQQHAKKAIQILELAQAIIAKMIE GGSSTGSGG 
KILELHAAFAIEMERMAAQMEEILQK GGSSGGSGG LQLEMHAKLAIELEEIAKQFERAEWL 
E 
HPG-9 
KILEKHAELAIALIAKFAEIVWEMEQ GGSNSGSGG EALAEHAQEAIAIFEAAIKEMQKAAA GGSSTGSGG 
AILQEHARIAIALAQIAKELAEMKQE GGSSGGSGG ALLKVHAEFAIKAQAMQEEAQEVLWQ 
E,C,P 
HPG-10 
EKLAQHAELAIQILEEALEMVWEIKK GGSNSGSGG QALAAHAAAAIELIQQMIRAVQEVIE GGSSTGSGG 
EQLAAHAEAAIAIRRIARQIAEIEEE GGSSGGSGG LLLQMHAIVAIAIERMKAAAEEIEWE 
E,C,P 
HPGA-3 
RQLAQHAKLAIKAAEKAEWAAKEAIR GGSNSGSGG ELLQQHAAIAIALMAIAIQIAERAKR GGSSTGSGG 
AILRIHAEMAILVKQAKQKALEAEAQ GGSSGGSGG ALLRLHAQMAIKFQEAEQAAKRALWQ 
E,C,P 
HPGA-9 
KILEKHAELAIALIAKAAEAAWEAEQ GGSNSGSGG EALAEHAQEAIAIFEAAIKEAQKAAA GGSSTGSGG 
AILQEHARIAIALAQAAKEAAEAKQE GGSSGGSGG ALLKVHAEFAIKAQAAQEEAQEALWQ 
E,C,P 
HPGA-10 
EKLAQHAELAIQILEEALEAAWEAKK GGSNSGSGG QALAAHAAAAIELIQQAIRAAQEAIE GGSSTGSGG 
EQLAAHAEAAIAIRRAARQAAEAEEE GGSSGGSGG LLLQMHAIVAIAIERAKAAAEEAEWE 
E,C,P 
1: NE = no expression, E = expression successful, C = fusion protein successfully cleaved, P = protein fully purified and stable 
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3.2 Materials and Methods 
3.2.1 Protein Preparation. Genes encoding all sequences were purchased from 
Biomatik, Inc. (Cambridge, ON) with an N-terminal TEV cut site and inserted between the 
BamHI and XhoI restriction sites of pET32a (+) (Novagen), which expresses proteins as His6-
tagged thioredoxin fusions.29 Site-directed mutants were generated using the Quickchange XL 
Site directed mutagenesis kit (Agilent Technologies, Santa Clara, CA). 
 Proteins were expressed in E. coli BL21 (DE3) in TPP media solution.40 Cells were 
grown at 37°C to an OD600 of approximately 1.0, induced with 1mM IPTG, and shaken at 25°C 
for an additional 4-5 hours. Cells were pelleted by centrifugation, lysed using a French press, and 
purified on a Ni-nitrilotriacetic acid column (Qiagen, Inc.). Initial attempts to perform Ni-NTA 
column purification under native conditions proved largely unsuccessful due to significant 
aggregation. A more productive strategy involving the use of a denaturing wash buffer (50mM 
NaH2PO4, 300mM NaCl, 20mM imidazole, 6M Urea, pH 8.0) and a denaturing elution buffer 
(50mM NaH2PO4, 300mM NaCl, 250mM imidazole, 4M Urea, pH 8.0) was ultimately adopted. 
The eluted fusion protein was dialyzed into 50mM Tris-HCl, 0.5mM EDTA, 0.5M Urea, 1mM 
DTT, pH 8.0 and then cleaved for at least 5 hours at 25°C with His6-tagged TEV protease 
(Invitrogen, Inc.). The post-cut protein mixture was then dialyzed into a low-urea wash buffer 
(50mM NaH2PO4, 300mM NaCl, 20mM imidazole, 1M Urea, pH 8.0) and filtered through Ni-
nitrilotriacetic acid resin. Purified protein was brought to a working concentration using a stirred 
pressure cell (EMD Millipore, Inc.), and dialyzed into 100 mM Tris, pH 8.0 for experiments. 
3.2.2  Solution Molecular Weight Determination. Oligomerization states were 
determined using size exclusion chromatography on a Shimadzu HPLC pump (Shimadzu Inc., 
Kyoto, Japan) equipped with a SPD-M20A diode array detector and a TSKGel G4000SW 125–5 
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300 x 7.5 mm column (Tosoh Bioscience LLC). Protein was eluted at a 0.5 ml/min flow rate and 
elution was monitored at 280 nm. The column was standardized using a gel filtration standard 
mix containing thyroglobulin, bovine γ-globulin, chicken ovalbumin, equine myoglobin, and 
vitamin B12 (Bio-Rad Laboratories, Inc). 
3.2.3 Heme Affinity Measurement and Complex Formation. Hemin stock solutions of 
approximately 0.5−1.0 mg/mL were prepared in DMSO and used within 6 h. Stock solution 
concentrations were determined using the pyridine hemochrome assay.41 In oxidized binding 
experiments, 0.5−2 μL aliquots of a hemin solution, consisting of approximately 0.1 molar equiv, 
were added via gastight syriange to a stirring 4 mL solution of 2−3 μM protein, with a 10 min 
equilibration delay between additions. Heme binding was monitored by the loss of absorption at 
385 nm due to free hemin, and the concomitant appearance of a sharp Soret band at 412 nm, 
corresponding to heme bound to the protein via bis- histidine axial coordination. The number of 
heme binding sites was quantified for each protein from plots of the Soret maximum at 412 nm 
versus the number of equivalents added. 
Binding affinities of ferrous hemes were determined using the method I described 
previously.42 Briefly, 9.0 mL of ∼3 μM protein was made anaerobic by extended flushing with 
nitrogen in a Dutton cuvette,43 and the solution potential was reduced to less than −450 mV 
versus NHE by the addition of a small volume (<20 μL) of sodium dithionite dissolved in 
degassed 100 mM KOH. The solution potential was monitored throughout the binding titration 
and kept below −450 mV by periodic additions of microliter volumes of sodium dithionite. 
Hemin was added in approximately 0.1 molar equiv aliquots, and spectra were recorded after a 
>10 min equilibration period. Kd,Red values were obtained from plots of the Soret band 
absorbance measured at 436 nm versus the concentration of hemin added and fit with equation 3: 
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(3) ∆𝐴 = Astart + εunb[hem] + εbnd[prot] ∙ [
Kd+[hem]+[prot]−√(𝐾𝑑+[hem]+[prot])2−4[hem][prot]
2[prot]
] 
 
For mixed hemin:chlorin and hemin:Zn(II)-protoporphyrin IX complex formation, single-
histidine knock-out protein samples bound to a single equivalent of hemin were first prepared as 
above. After addition of a full equivalent of heme, these samples were then passed over a PD-10 
desalting column (GE Healthcare, Piscataway, NJ) to remove excess DMSO. Protein-heme 
complex concentrations were calculated using the bound heme Soret peak at 412 nm. 
3.2.4 Fluorescence Spectroscopy. Fluorescence spectra collected as a function of heme 
oxidation state were performed on an Olis DM 45 spectrofluorimeter running Olis GlobalWorks 
software.  Solutions were degassed under a flow of N2, and further O2 removal was carried out 
using a glucose oxidase/catalase enzymatic system44 consisting of 2% glucose with 25 units/ml 
glucose oxidase, and 250 units/ml catalase45,46 in the cuvette. Proteins were reduced using 0.20 
mM NADPH and 0.25 µM Ferredoxin-NADP reductase.  Reduction was verified by UV-Vis 
spectra.  Cofactor fluorescence intensities were recorded with 0.6 mm and 1.24 mm slits width 
for excitation and emission respectively.  Excitation wavelengths of 550 nm, 600 nm, and 630nm 
were used for Zn(II)-protoporphyrin IX, Zn(II) chlorin e6, and zinc phthalocyanine cofactors 
respectively. 
3.2.5 Determination of Reduction Potentials. Potentiometric titrations were performed 
using the method of Dutton:43 Concentrated solutions of hemoprotein prepared in advance were 
diluted to 20−30 μM into a solution containing the corresponding apoprotein (>100 μM) to 
eliminate the possibility of heme dissociation upon reduction.42 Mediator concentrations were: 
2,3,5,6-tetramethylphenylenediamine (25uM), 1,2-napthoquinone (25uM), phenazine 
methosulfate (20uM), Duroquinone (50uM), Pyocyanine (1uM), Indigotrisulfonate (1uM), 
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indigo carmine (1uM), indigotetrasulfonate (1uM), 2-hydroxy-1,4-napthoquinone (25uM), 
phenazine (20uM), anthroquinone-2-sulfonate (20uM), benzyl viologen (1uM), and methyl 
viologen (1uM). Reported reduction potentials are referenced to the standard hydrogen electrode. 
All titrations were performed anaerobically using microliter additions of freshly prepared sodium 
dithionite to adjust the solution potential to more negative values and potassium ferricyanide to 
more positive values. Potentiometric titrations were analyzed by monitoring the absorbance band 
at 558 as the heme protein was reduced or oxidized. The data were fit with the Nernst equation 
using an n value of 1.0. 
3.2.6 Circular Dichroism Spectroscopy. Circular dichroism spectra were recorded on a 
JASCO J-810 sepectropolarimeter in a quartz cell of 0.1cm light-path, using a bandwidth of 1nm 
and a scan speed of 50nm/min. Protein solutions were 10-20 µM. Spectra were collected 
between 200nm and 350nm with background correction and observed as ellipticity (obs, mdeg). 
The mean residue ellipticity ([],degcm2dmol-1) were calculated using Eq. 3 below where 
MRW is the mean residue molecular weight, c is the sample concentration in mg/ml, and l is the 
light-path length of the cell in cm. 
 
 (3) []=[]obs [MRW/(10lc)] 
 
Protein secondary structure percentages were calculated with the program K2d 47 using data 
points ranging from 200nm to 240nm. 
3.2.7 Nuclear Magnetic Resonance Spectroscopy. All NMR experiments were 
performed at 20oC on Varian Inova spectrometer operating at a 600MHz and equipped with a 
triple resonance cryogenic probe capable of applying pulse field gradients in the z-direction. 
Chemical shifts are referenced to water at 4.77 ppm for 1H. Data were processed using the 
program NMRPipe 48 and analyzed using Sparky.49 Unlabelled protein samples were exchanged 
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into deuterium oxide buffer containing 200 mM d9-Tris, pD 8. All samples were 300-400 µM in 
four-helix bundle concentration. One-dimensional 1H spectra and two-dimensional 1H-13C 
sensitivity-enhanced constant-time heteronuclear single-quantum coherence (13C-HSQC) spectra 
were collected as described previously.15  
For histidine side chain rotamer determination 4D 13C/13C separated HMQC-NOESY-
HMQC spectra 50 were collected on reduced U-13C,15N-L-histidine-labelled holoprotein samples 
with sweep widths of 10,000 Hz for 1H and 2000 Hz for 13C utilizing Wurst140 decoupling of 
the full 13C spectral width (140ppm) and a mixing time of 150 ms. Reduced samples were 
prepared by degassing in a 9 inch NMR tube using multiple cycles of vacuum and argon, 
reducing with excess dithionite and then flame sealing.  
 
3.3. Solubility and Heme Binding in Algorithmically Generated Sequences 
 Of the ten sequences discussed above, three did not express even at lowered (16°C) 
temperatures. Of the seven that did express, five were soluble as thioredoxin fusions after 
denaturing purification. And of these five soluble fusion proteins, three were soluble after 
cleavage from the thioredoxin domain: HPG-3, HPG-9, and HPG-10. CD analysis of these three 
proteins confirms their helical nature (Fig 4) and size exclusion chromatography demonstrates 
that they are monomeric. Attempts to refold the other proteins in the presence of hemin in order 
to enhance solubility or structural stability proved unsuccessful. 
 Each of the three soluble proteins was assayed for ferric heme binding. No binding is 
observable as detected by the appearance of a bis-histidine Soret peak at or near 412 nm after 24 
hour incubations at a range of temperatures and solvent pH values. Results from my previous 
work 51 and that of others 52 has demonstrated that many designed proteins feature an over-
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stabilized apo state with low solvent accessibility to the binding pocket. Thus, significant 
chemical denaturation is often required to coerce the protein into an open conformation where 
binding can occur.52-54 However, attempts to partially destabilize the proteins in order to increase 
the stability of this open state, using urea and guanidine hydrochloride in combination with 
elevated temperatures as has proven successful for other designed proteins, were likewise 
unsuccessful. 
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3.4 HPGA Sequences: Binding Pocket Redesign 
Figure 3. Opening a cavity for porpyryn-biding in the protein core. (A) An unminimized model of HPG-9 with 
fixed consensus sequence positions shown in red. Large hydrophobic residues on adjacent helices, likely to be a 
steric hinderace to porpyryn binding, are highlighted with gold spheres. (B) An unminimized model of HPGA-9, 
where problematic residues of part A have been mutated to alanine. (C) The pattern of residue positions used in the 
HPG library, where Z = core, U = surface, and X = interface. Fixed consensus sequence positions are shown in 
magenta. (D) The pattern of residue positions used for the HPGA and subsequent libraries, with an expanded set of 
fixed residue identities shown in magenta. 
 
 
 
The failure of HPG-3, HPG-9, and HPG-10 to exhibit ferric heme binding even after 
treatment with denaturants suggests that while the T73 consensus sequence may be necessary, it 
is not sufficient to ensure bis-histidine porphyrin binding between alpha helices. Thus, it is likely 
that more sequence information must be specified. Figure 3A depicts a simple, unminimized 
model of HPG-9 in which each side chain is in its lowest energy helical rotamer.39 The 
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bioinformatically derived sequences that were used in this design process only fix residue 
identities in the helices which contain the ligand side chains. For this reason, possible steric 
clashes with nonligand helices were not considered in the original design of the binding pocket. 
From Figure 3A, it is clear that three positions on each nonligand helix pose a high risk of steric 
hindrance to binding.  
 To remedy this, each of the three soluble proteins was altered by alanine mutation at each 
side chain position that was identified as a possible obstruction (see Figure 3B, sequences in 
Table 3). All three of these proteins, the new versions of which are termed HPGA-3, HPGA-9, 
and HPGA-10 (see Table 3), are soluble monomers when cleaved from their fusion partners and 
are more alpha helical as assayed by circular dichroism (Figure 4). The latter is not surprising, as 
several side chains have been replaced with the one known to have the highest helical 
propensity.55 
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Figure 4. Circular dichroism spectra for (A) HPG-3 (gray) and HPGA-3 (black), (B) HPG-9 (gray) and HPGA-9 
(black), and (C) HPG-10 (gray) and HPGA-10 (black) apo proteins. (D) A table of alpha helical content (in percent) 
for each protein, as calculated by the K2d software package.47 In all sequences, alanine mutations result in an overall 
increase in helical content.
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3.5 Heme Affinity and Binding Pocket Characterization 
 
Figure 5. Single-site ‘knock-out’ binding sequences of HPGA-9 and HPGA-10. (A) Sequences with a deactivated 
binding site between helices 1 and 3. ‘Knock-out’ phenylalanine mutations are indicated in red, and preserved 
hisitdine positions are in bold. (B) Sequences featuring a deactivated binding site between helices 2 and 4. Cartoon 
insets indicate the location of functional binding sites.  
 
 
 
Of the three alanine-mutated proteins, HPGA-9 and HPGA-10 both bind heme in an 
oxidized and reduced state. HPGA-9 binds two equivalents while HPGA-10 binds only one. 
‘Knock-out’ mutations were made to each binding site of each sequence by replacing one or both 
of the ligating histidines with phenylalanine (Figure 5). These mutations allow us to determine 
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the binding constants independently for each site in HPGA-9. The fact that only one such knock-
out sequence in HPGA-10 can bind heme indicates that the sole functional binding site of that 
protein lies between the second and fourth helices (not shown). 
 
Figure 6. Characterization of heme binding in HPGA-10. (A) Bound heme spectra in both oxidized and reduced 
states. (B) Oxidized heme binding titration of HPGA-10 (circles), fit with equation 3 (red line). (C) Determination 
of bound heme reduction potential, fit with the single-electron Nernst equation (red line). (D) Reduced heme binding 
titration, fit with equation 3. Inset is a cartoon diagram of HPGA-10, indicating the location of the functional 
binding site. 
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Figure 6 above depicts the bound heme spectra in both the ferric and ferrous states, the 
determination of the ferric and ferrous heme binding constants, and the bound heme reduction 
potential of the single heme that binds HPGA-10. The bound heme reduction potential, -146 mV 
vs NHE (see Table 5), is more than 100mV more positive than observed in previous heme 
protein designs.56-58 Gibney and coworkers have demonstrated that the bound heme reduction 
potential directly determines the ratio of oxidized and reduced heme binding affinity59,60 with 
higher potential heme-protein complexes having weaker ferric and stronger ferrous affinities. My 
findings for HPGA-10 reflect this, with reduced heme dissociation constants within error of 
those observed for my previous intentionally designed hemoproteins HP7 58 and H4,34 and 
oxidized binding 5-fold to 10-fold weaker. 
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Figure 7. Characterization of heme binding in HPGA-9. (A) Representative bound heme spectra in both oxidized 
and reduced states. (B) Reduced heme binding titration for the binding site located between helices 1 and 3 (circles) 
fit with equation XX (red line). Inset is the corresponding oxidized binding titration for this site, wherein binding is 
too tight to reliably fit with equation XX. (C) Potentiometric titration of the diheme protein (both binding sites 
intact), fit with a single-site, single-electron Nernst equation (red line). (D) Reduced heme binding titration for the 
binding site located between helices 2 and 4 (circles) fit with equation XX (red line). Inset is the corresponding 
oxidized binding titration for this site.  
 
 
HPGA-9 binds two molecules of hemin. Due to the large degree of spectral overlap and 
the similar binding constants at the two binding sites, the two HPGA-9 binding site knock-out 
proteins were used to independently determine their ferric and ferrous heme affinities (see Figure 
5). The reduction potentials at the two sites are the same, within error, of each other. Figure 7C 
depicts the potentiometric titration of the diheme protein fit with a single one-electron transition. 
The fit potential is the same as those independently determined for the two single heme knock-
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out proteins (not shown). This demonstrates that binding of either heme has little effect on the 
global structure of the protein, a property distinct of that seen in other designed diheme four α-
helix bundles.61,62 
 
Table 4. Heme binding constants for the functional binding sites of HPGA-9 and HPGA-10.  
Protein Location Kd Oxidized 
 
Kd Reduced 
(μM) 
Em 
(mV) 
HPGA-9 Helices 1-3 25.2 +/- 9 nM 1.5 +/- 0.4 -168 +/- 3 
HPGA-9 Helices 2-4 77.3 +/- 16 nM 4.6 +/- 0.5 -168 +/- 3 
HPGA-10 Helices 2-4 3.5 +/- 1.2 μM 3.8 +/- 0.2 -146 +/- 4 
 
As the data above shows, half of the binding sites in soluble sequences successfully 
bound heme after modification of the binding pocket. An inspection of the sequence features of 
the unsuccessful binding sites suggests that large or charged residues at certain nearby positions 
might disrupt heme binding. In HPGA-10, binding might be disrupted between helices 1 and 3 
due to GLN at position 2, approximately one helical turn ‘above’ the ligating histidine at position 
6. In HPGA-3, the presence of LYS at position 2 and GLU on the adjacent helix 3 at position 71 
might prevent binding in much the same way. In a similar manner, between helices 2 and 4, the 
presence of LEU at positions 37 and 106 might contribute to the disruption of binding. 
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3.6 Structural Characterization 
3.6.1 Backbone Structural Specificity. Although backbone 15N-HSQC spectra are 
commonly used to demonstrate structural specificity in proteins,12,63 neither HPGA-9 nor HPGA-
10 were soluble at solution pH levels low enough to prevent amide proton exchange with solvent 
on the NMR time scale. Figure 8 depicts the the natural abundance 13C-HSQC spectrum of 
diheme HPGA-9. The low level of chemical shift dispersion observed in Figure 8A and B 
coupled with the similarity of the apo and holoprotein spectra indicate that HPGA-9 does not 
undergo a large structural organization upon heme binding, and may not adopt a single nativelike 
holo state.  
 
Figure 8. Natural abundance 13C-HSQC spectra of (A) apo and (B) holo HPGA-9 samples. Similarity between the 
spectra indicates that HPGA-9 does not undergo a large structural change upon binding. 
 
 
3.6.2 Geometry of Porphyrin-Ligating Residues. As outlined in Section 2.2, the HPG 
sequences were designed to enforce the bis-his ligation of heme with histidines in the T73 
rotamer. In HPGA-10, this design feature was confirmed by directly probing its histidine 
geometry via NMR spectroscopy. A ‘knock-out’ version of the HPGA-10 sequence was prepared 
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where both histidines in the inactive binding site (HIS6 and HIS76) were mutated to 
phenylalanine (Figure 5). This sequence, HPGA-10-H6FH76F, was then expressed to selectively 
incorporate uniformly 15N, 13C-L histidine residues into the functional binding site.64 Four-
dimensional 13C/13C separated HMQC-NOESY-HMQC NMR spectra were then collected on 
reduced holoprotein samples.50,65  
 
Figure 9. Structural characterization of heme-bound histidine geometry in HPGA-10H6FH76F. (A) 13C-HSQC 
spectra of labeled HPGA-10H6FH76F, showing the chemical shifts of the carbon atoms of H41 and H111. (B) 
13C/13C HMQC-NOESY-HMQC spectra of reduced holo HPGA-10H6FH76F, showing selected crosspeaks between 
nearby carbon-bound protons of H41 and H111.
 
 
In this experiment, cross-peak intensities indicate the relative distances between the 13C-
bound protons within labeled residues according to equation 4, where 𝑟𝑖 is an unknown 
interproton distance, 𝑟𝑟𝑒𝑓 is a known interproton distance, and 𝑆𝑟𝑒𝑓 and 𝑆𝑖 are their respective 
NOE cross-peak intensities.66 
(4) 𝑟𝑖 = 𝑟𝑟𝑒𝑓 (
𝑆𝑟𝑒𝑓
𝑆𝑖
)
1/6
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Figure 10 below shows the relevant carbon-bound 1H-1H distances for the T73, M166, T86 and 
M80 rotamers as defined by Negron et al.30 With respect to the interproton distances of all the 
rotamers in this group, T73 is distinguished primarily by a large (4.7Å) separation between its 
Cβ and Cδ-bound protons (Figure 10A). Moreover, in all of these configurations, the Cε-bound 
proton and the Cδ-bound protons maintain a constant distance of 4.3Å since they are both bound 
to the imidazole ring. Using 1Hε-1Hδ and 1Hβ-1Hδ cross-peak intensities as 𝑆𝑟𝑒𝑓 and 𝑆𝑖 
respectively, it is therefore possible to determine the characteristic 1Hβ-1Hδ interproton distance. 
Using the cross-peak intensities from the spectra shown in Figure 9B above, this separation was 
calculated to be 4.6Å. Thus, it is likely that the ligating histidines in HPGA-10 adopt the 
extended histidine conformation of the T73 rotamer.  
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Figure 10. Important inter-proton distances for representative models of the histidine rotamers identified by Negron 
et al.30 Shown are the distances between Ca, Cb, and Cd-bound protons for the (A) T73, (B) M166, (C) T86, and (D) 
M80 rotamers.
 
 
3.7 Electron Transfer in Mixed-Cofactor Complexes 
 The HPG/HPGA proteins were designed to support electron transfer between cofactors. 
As a prerequisite, they must be capable of simultaneously accommodating a heme and a separate 
cofactor that can serve as a light-activated primary donor in the electron transfer reaction. 
Previous work has demonstrated that zinc porphyrin cofactors can be bound at de novo designed 
bis-histidine binding sites by eliminating one of the ligating histidines.34,67 Accordingly, a single-
histidine knock-out of HPGA-9 (HPGA-9-H111F in Figure 5), which features a functional bis-
histidine binding site and a monohistidine site, was selected for further screening. To check for 
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complex formation, HPGA-9-H111F was loaded with one equivalent of heme at the bis-histidine 
site and separately titrated with Zn(II)-protoporphyrin IX, Zn(II)-chlorin e6, Zn-phthalocyanine 
and Zn-tetraphenylporphyrin. Figures 11A and 11B below show that Heme: Zn(II)-
protoporphyrin IX and Heme: Zn(II)-chlorin e6 complexes can be formed without disruption of 
the heme site.  
Fluorescence intensity assays were performed to determine if these complexes are 
capable of electron transfer. Specifically, if the photoexcited state of the Zn(II) porphyrin 
cofactor can relax via electron transfer to the heme, then reduction of the heme should block this 
relaxation pathway. Therefore, an increase in flourescense intensity of the Zn(II) cofactor in the 
reduced complex is evidence for electron transfer.68 Figures 11C and 11D show such an increase 
in florescence intensity going from the oxidized (black) to reduced (red) states in both 
complexes. 
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Figure 11. (A) Absorbance spectra of the Hemin:Zn(II)-protoporphyrin IX complex of HPGA9-H111F in the 
oxidized (black) and reduced (red) states. (B) Absorbance spectra of the Hemin:Zn(II)-chlorin e6 complex of 
HPGA9-H111F in the oxidized (black) and reduced (red) states. (C) Oxidized (black) and reduced (red) 
fluorescence emission spectra of the Hemin:Zn(II)-protoporphyrin IX complex excited at 418nm, showing an 
increase in fluorescence emission intensity when heme is reduced. (D) Oxidized (black) and reduced (red) 
fluorescence emission spectra of the Hemin:Zn(II)-chlorin e6 complex excited at 418nm, showing an increase in 
fluorescence emission intensity when heme is reduced. 
 
 
3.8 Conclusions 
 The above results demonstrate that sophisticated functions such as cofactor binding and 
electron transfer can be engineered into a protein by specifying only a small number of fixed 
amino acids in its sequence. In order to draw useful conclusions for future protein design 
projects, it is instructive to look at the success rate of this approach compared to those of other 
similar protein design efforts. Of all thirteen sequences generated, two were shown to bind heme 
 36 
with a satisfactory level structural specificity. Of these two successful proteins, HPGA-9 was 
capable of accommodating a variety of photoactive Zn(II) porphyrin cofactors and was further 
shown to exhibit light-activated electron transfer between cofactors. Therefore, this procedure 
can be considered to have a 15% success rate for cofactor binding, or an 8% success rate for 
electron transfer function.  
A brief survey of success rates from other modern de novo design efforts shows rates 
ranging from 2 - 44%, with most surveyed methods yielding fewer than 15% successful 
sequences.69-73 Such a comparison of success rates is inherently complicated by small sample 
sizes and the differing criteria for success across projects. Nevertheless, the above numbers 
indicate that a propensity-weighted patterning approach to protein design, such as I describe, 
yields successful sequences with a frequency similar to other more computationally expensive 
methods. 
 One advantage of this method is that it generates sequences from a discrete probability 
distribution of amino acids, thereby permitting a rough estimation of the possible number of 
functional proteins it can produce. Assuming that 8% of sequences are capable of both heme 
binding and electron transfer, and using the alanine-mutated sequence pattern shown in Figure 
3D, it is estimated that 5.6 x 1045 distinct functional proteins can be generated with this 
procedure.  
This astronomical number represents a volume in ‘sequence space’ much too large for 
evolution to have explored, and this study implies that evolution did not need to exhaustively 
search this space in order to achieve functional success. With respect to de novo protein design, 
this is evidence that a successful strategy need not account for the numerous unnecessary 
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constraints associated with the long evolutionary history of natural proteins; functional 
sequences only require the explicit identification of a few key residues.   
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Chapter 4. Next Generation Sequence Libraries: Charge and Hydrophobicity 
 
4.1 Net Charge and Hydrophobicity in Designed Protein Sequences 
 Given the large number of functional sequences that can be produced by the design 
procedure described in Chapters 2 and 3, an 8% success rate implies that a proportionally larger 
number of candidate sequences must be expressed and tested before functional proteins can be 
identified. This presented a significant challenge to the experimental verification of this protein 
design protocol and highlighted the need for improvements. In the library of designed sequences 
shown in Table 3, only three of the ten members of the HPG library were soluble enough to be 
fully purified. Thus, to a first approximation, any attempt to improve this procedure first has to 
address the issue of protein solubility.  
 In 2007, Liu and coworkers demonstrated that placing a large number of similarly 
charged amino acids at solvent-exposed positions in natural proteins was sufficient to prevent 
their aggregation in the unfolded state and impart remarkable resilience in the form of refolding 
after denaturation.1 This ‘supercharging’ technique resulted in net charge counts ranging from 
+48 to -30, yet these highly modified proteins retained the function of their wild-type 
counterparts. The dual benefits of solubility and resilience may come at the cost of overall 
structural stability, however, as repulsion between residues of a similar net charge is known to 
decrease stability in natural proteins74 and extreme net charge has been identified as a hallmark 
of intrinsically disordered protein sequences.75  
 De novo designed proteins generally feature a number of energetically favorable 
interactions that stabilize a native folded state and, as such, are usually more stable than 
comparable natural proteins. The incorporation of high net charge into a protein design scheme 
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may therefore be a promising strategy to increase solubility in designed proteins, as their 
inherent stability may account for the effects of their net charge.  
 The folding of globular proteins is stabilized primarily through the burial of nonpolar 
residues into a hydrophobic core.76 These hydrophobic interactions are nonspecific, and the 
presence of many nonpolar residues might therefore lead to multiple conformations of the 
polypeptide chain that are more stable than the unfolded state.77 For many sequences in the HPG 
library, the observed propensity for aggregation suggests that an amyloid-like state might be the 
most stable conformation of the protein chain. Therefore, a decrease in overall hydrophobicity 
might destabilize such aggregates and promote a more soluble monomeric native state in 
generated sequence libraries.  
 
4.2 Modifications to the Sequence Generation Algorithm 
 The effects of modulating net charge and hydrophobicity in the aforementioned design 
process were explored via modifications to the procedure of Chapter 2. First, the optimal heme 
binding site consensus sequence (Section 2.2) was expanded to include the alanine residues on 
non-ligating helices near each binding site (Section 2.4). Next, to probe the effects of net charge 
on protein solubility, a library of ten sequences was generated with this consensus sequence and 
with the rule that each of the four helical regions should separately have a net charge of at least 
+5 or at most -5 for net positive or net negative sequences, respectively. The original amino acid 
probability distribution shown in Table 2 was used. The ten sequences (HS-1 to HS-10) resulting 
from this modification to the charge cutoff rule are shown in Table 6.  
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Table 5. The HS protein sequences, and the steps in the purification process that were possible for each sequence. Helical regions are underlined and fixed amino 
acid identities are highlighted in bold for each sequence. 
Name Sequence Purification 
Step1 
HS-1 
AALEEHAKLAIRIIRQALRAAKKAIK GGSNSGSGG QKLRAHARQAIKALEAAIKAALQAKQ GGSSTGSGG  
AQLKAHARMAILLRKALKLAQQAAEK GGSSGGSGG LKLRAHAQVAILLRQAARLAKQALKL 
E,C 
HS-2 
RALERHARKAIQFLRAALAAAKAAKE GGSNSGSGG QILRKHARLAIRIAAKAIKQAQRAIA GGSSTGSGG 
EALKKHAKLAIIIERAERIAIRAARR GGSSGGSGG KALRMHAALAIQVQQALAKAAKAQKA 
E,C 
HS-3 
EALREHAQKAIRMQRKAQRAAKQAAQ GGSNSGSGG RILQRHAKIAIRVIKLAAELAKKALR GGSSTGSGG 
RALKLHAQMAIQVREAQKIAAAAARR GGSSGGSGG LALKMHAKAAIIFKKAQQQARAAKAE 
E,C 
HS-4 
AKLREHAEKAIKIKRQAQEAAAKALK GGSNSGSGG RKLAQHAQQAIAIARKALRLAQQALA GGSSTGSGG 
KLLKEHAQAAIKFKAAKREAAQAIRR GGSSGGSGG EILRMHAKLAIKFQAAAQAAKKAAAK 
E,C 
HS-5 
EQLRKHAEKAIKLQAAALRAAKAAKQ GGSNSGSGG QQLREHAQKAIKLVKEAIRQAIKAIR GGSSTGSGG 
QLLREHARMAIQFRAAQAIAAKAKKA GGSSGGSGG AQLQMHAAVAIILERAQKIAKRAQRK 
E,C 
HS-6 
EILQQHAQLAIQAEAQAQEAAQEAAE GGSNSGSGG ALLEQHAQIAIKIVEAAEEIAQEAAE GGSSTGSGG 
AELQEHAEIAILIKQAQEEAQAAIQE GGSSGGSGG IQLEFHAEIAIEFERAEEEAAQAKAA 
E,C,P 
HS-7 
EALEEHAELAIEALEIAQEAAKQAKA GGSNSGSGG AILAEHAKAAIQIVEEALQEAQEALE GGSSTGSGG 
QELEIHARFAIALAEAAEAAQQAEAE GGSSGGSGG EELEMHAAIAIQLEQALEEARRAEEQ 
E,C,P 
HS-8 
QELERHAAQAIAMEQKALQAAEEAEE GGSNSGSGG EALERHAEIAIEIMEEAEELALKAQK GGSSTGSGG 
RILEIHAEIAIAIEEAEKAAEAAAAE GGSSGGSGG IALEIHAAIAIAVQEAEEIAEKAEQE 
NE 
HS-9 
EILQAHAEIAIALEALAIAAAALAEE GGSNSGSGG EELEAHAEAAIRFAALAEEQAAQALQ GGSSTGSGG 
EELQEHARLAIEAREALEQALEAIER GGSSGGSGG QLLAVHAQFAIAMEEALEQAAEAAQE 
E,C,P 
HS-10 
EELEEHAQAAIALLELAQAAAAIAQA GGSNSGSGG QELKEHAAEAIAIAEAAEELAQEALK GGSSTGSGG 
EQLEIHAEFAIQAEEAAEAAEEAQKK GGSSGGSGG EQLQLHALMAIKFKQAEEEAEEAQEL 
E,C,P 
HS-7-W 
EALEEHAELAIEALEIAQEAAWQAKA GGSNSGSGG AILAEHAKAAIQIVEEALQEAQEALE GGSSTGSGG 
QELEIHARFAIALAEAAEAAQQAEAE GGSSGGSGG EELEMHAAIAIQLEQALEEARRAEEQ 
E,C,P 
HS-9-W 
EILQAHAEIAIALEALAIAAAWLAEE GGSNSGSGG EELEAHAEAAIRFAALAEEQAAQALQ GGSSTGSGG 
EELQEHARLAIEAREALEQALEAIER GGSSGGSGG QLLAVHAQFAIAMEEALEQAAEAAQE 
E,C,P 
HS-10-W 
EELEEHAQAAIALLELAQAAAWIAQA GGSNSGSGG QELKEHAAEAIAIAEAAEELAQEALK GGSSTGSGG 
EQLEIHAEFAIQAEEAAEAAEEAQKK GGSSGGSGG EQLQLHALMAIKFKQAEEEAEEAQEL 
E,C,P 
1: NE = no expression, E = expression successful, C = fusion protein successfully cleaved, P = protein fully purified and stable 
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Finally, another separate library of sequences was generated to explore the additional 
effect of lowering the overall hydrophobic content of our protein sequences. In this case, the 
original discrete probability distribution for amino acid occupancy shown in Table 2 was 
modified to exclude the hydrophobic residues leucine and isoleucine from occupying interfacial 
(neutral) positions. The resulting distribution is shown in Table 7 below. The ten sequences 
(HSH-1 to HSH-10) shown in Table 8 were then generated using this new probability 
distribution as well as the modified net charge cutoff rule and expanded consensus sequence, as 
described above. 
 
Table 6. Modified amino acid probability distributions for each position category in the HSH protein library. Each 
entry represents the probability (normalized to 100%) that the corresponding residue will appear in the given 
position category.  
Residue Core Probability Surface Probability Interface Probability 
A 15.8 20.6 28.4 
E 0.0 21.3 21.5 
F 13.8 0.0 0.0 
I 17.4 0.0 0.0 
K 0.0 19.5 23.2 
L 19.3 0.0 0.0 
M 20.1 0.0 0.0 
Q 0.0 19.7 26.9 
R 0.0 18.7 0.0 
V 13.4 0.0 0.0 
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Table 7. The HSH protein sequences and the steps in the purification process that were possible for each sequence. Helical regions are underlined and fixed 
amino acid identities are highlighted in bold for each sequence. 
Name Sequence Purification 
Step1 
 
HSH-1 
RKLKKHAEEAIAMKRKAKKAAREAER GGSNSGSGG AQLARHARQAIAAVKAAERAAARAQR GGSSTGSGG  
AALEKHAKMAIKMQAAARKAERAKKA GGSSGGSGG KALKMHAQLAIQIAKAAQQAAQAAKK 
 
 
E,C,P 
 
HSH-2 
KALAQHARAAIKFQQEAKKAARQAER GGSNSGSGG KQLRQHAQAAIAMMAAAQRAAARAKR GGSSTGSGG 
KALEEHARLAIAAKKAAKKAQQAAQK GGSSGGSGG KQLEIHAQMAIAARKAQRQAKQAQKA 
 
 
E,C 
 
HSH-3 
AKLRRHAEEAIEVQKKAAQAARAAKK GGSNSGSGG RALREHAEAAIRVMRQAKKQAQQAKR GGSSTGSGG 
AKLEAHARIAIQARQAKKEAQQAKRR GGSSGGSGG EKLRVHAQFAIAVKKAAQQAKRAKQA 
 
 
E,C 
 
HSH-4 
AKLRKHAEAAIRAKQQAAAAARAAQQ GGSNSGSGG AQLKKHARAAIEVLRAAAKAAQKAKR GGSSTGSGG 
RELAKHAKMAIKLEAAARKAARAAKQ GGSSGGSGG EKLKLHAKMAIQVRRAAQAAQKAQEK 
 
 
E,C 
 
HSH-5 
RQLKKHAEAAIQLARKAEQAAQKAQK GGSNSGSGG AQLKEHAAAAIKMFAQAKEKAQRAKK GGSSTGSGG 
RALEEHAKFAIKVRKAEKKAEQAKKQ GGSSGGSGG KKLEMHAAMAIEMAAAQRQARKAKRQ 
 
 
E,C 
 
HSH-6 
EELQAHAKEAIAAKEQAAEAAEEAQQ GGSNSGSGG QELEEHAAKAIEVAEQAQEEAQEAEQ GGSSTGSGG 
QALAQHAQMAIAAEQAEEEAEKAEQE GGSSGGSGG EALELHAKIAIAAERAAEQAEEAAEQ 
 
 
E,C,P 
 
HSH-7 
KELQEHAEEAIQAEKAAEEAAEQAEA GGSNSGSGG EALAEHAKAAIQLMEEAEEAAEQAQR GGSSTGSGG 
RALEEHAELAIQLEAAAEAAEEAQAA GGSSGGSGG QELAMHAEAAIKAQEAAAQAEEAQEQ 
 
 
E,C,P 
 
HSH-8 
EQLRQHAEQAIEMAEQAKEAAEKAEE GGSNSGSGG RELEEHAAQAIQVMAQAEEQAERAAE GGSSTGSGG 
QALEQHAQMAIELERAAEAAEAAEAA GGSSGGSGG AALEFHAEFAIAMAEAKREAEQAEAE 
 
 
NE 
 
HSH-9 
AALQQHAEAAIALQAEAAEAAEQAAE GGSNSGSGG AELEQHAEQAIKAIEEAEAQAARAEA GGSSTGSGG 
EALQAHAQMAIEAREAAEAAEQAEAE GGSSGGSGG EELELHAQLAIKMREAEEQAQQAKEE 
 
 
E,C,P 
 
HSH-10 
EALAEHAAQAIAIEEQAQKAAEQAEE GGSNSGSGG EELAEHAEQAIQAFREAAEAAQAAEQ GGSSTGSGG 
QALEEHAEAAIEMRKAAEEAAQAQEA GGSSGGSGG QALEFHAALAIAVQQAQAQAEEAEEQ 
 
 
E,C,P 
 
HSH-1-W 
 
RKLKKHAEEAIAMKRKAKKAAWEAER GGSNSGSGG AQLARHARQAIAAVKAAERAAARAQR GGSSTGSGG  
AALEKHAKMAIKMQAAARKAERAKKA GGSSGGSGG KALKMHAQLAIQIAKAAQQAAQAAKK 
 
E,C,P 
1: NE = no expression, E = expression successful, C = fusion protein successfully cleaved, P = protein fully purified and stable 
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4.3 Materials and Methods 
4.3.1 Protein Preparation. Genes encoding all twenty sequences were purchased from 
Biomatik, Inc. (Cambridge, ON) with an N-terminal TEV cut site inserted between the BamHI 
and XhoI restriction sites of pET32a (+) (Novagen), which expresses proteins as His6-tagged 
thioredoxin fusions.29 Site-directed mutants were generated using the Quickchange XL Site 
directed mutagenesis kit (Agilent Technologies, Santa Clara, CA). 
 Protein purification via Ni-NTA column was performed according to the protocol 
described in Section 3.2.1 above, with the following two modifications: 1) His6-tagged fusion 
proteins were purified under native conditions using traditional wash (50mM NaH2PO4, 300mM 
NaCl, 20mM Imidazole, pH 8.0) and elution (50mM NaH2PO4, 300mM NaCl, 250mM 
Imidazole, pH 8.0) buffers; and 2) fusion proteins were cleaved under native conditions in 50mM 
Tris-HCl, 0.5mM EDTA, 1mM DTT, pH 8.0.  
4.3.2 Nuclear Magnetic Resonance Spectroscopy. Uniformly 15N labeled samples were 
prepared in 100mM NaH2PO4, 50mM NaCl, pH 6.0 with 10% D2O added before data 
collection. Two-dimensional 1H-15N sensitivity-enhanced constant-time heteronuclear single-
quantum coherence (15N-HSQC) spectra were collected as described previously.29 
 
4.4 Characterization of Next Generation Sequences 
4.4.1 Solubility and Heme Binding. The expression and purification results for the HS 
and HSH libraries are shown in Table 6 and Table 8, respectively. Of the ten sequences in the HS 
library, four were successfully expressed and purified. With the exception of HSH-8, which 
could not be overexpressed, all of the negatively charged sequences in the library remained 
soluble throughout the entire purification process. Of the soluble HS sequences (HS-6, HS-7, 
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HS-9, and HS-10), three sequences (HS-7, HS-9, and HS-10) were found to bind heme in a 
preliminary assay (Figure 12). In order to correctly determine the solution protein concentration 
and thus quantify the stoichiometry of binding, each sequence was mutated to include a 
tryptophan residue at the end of the first helix (Table 6). In all three cases, the sequences were 
found to bind one molecule of heme per four-helix bundle. 
 
Figure 12. Heme binding in the HS protein library. Selected spectra are characteristic of bound heme in the 
presence of (A) HS-7, (B) HS-9 and (C) HS-10.  
 
 
 Five out of the ten sequences in the HSH library could be successfully expressed and 
purified. As with the HS library, the majority of the soluble sequences were highly negatively 
charged with the notable exception of the positively charged HSH-1 sequence. Of these soluble 
sequences (HSH-1, HSH-6, HSH-7, HSH-9, and HSH-10), only the positive sequence HSH-1 
was found to bind heme. As with the HS proteins, this sequence was found to bind one molecule 
of heme per four-helix bundle. 
4.4.2 Structural Characterization. HS-7, HS-9, and HS-10 were soluble at high 
concentrations at pH 6.0 and thus permitted the collection of 15N-HSQC spectra as shown in 
Figure 13 below. As the solubility of HSH-1 was highly limited at pH 6.0, no acceptable data 
could be produced on the backbone structural specificity of this sequence. HS-9 and HS-10 in 
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particular exhibit a high degree of chemical shift dispersion in the apo state, and appear to 
undergo further structural changes upon heme binding.  
The negatively charged HSH sequences (HSH-6, HSH-7, HSH-9, and HSH-10) were 
assayed for helical content via CD spectroscopy. Their spectra (Figure 14) are characteristic of a 
random coil backbone conformation, even at increased salt concentrations (not shown). These 
spectra may serve to explain the lack of heme binding observed in these sequences, as they lack 
the requisite secondary structure for a molten globular apo state.  
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Figure 13. NMR structural characterization of the soluble, heme-binding HS series proteins. (A) 15N-HSQC 
backbone spectra of uniformly 15N-labeled apo HS-7, and (B) the corresponding spectra of holo HS-7. (C) 15N-
HSQC backbone spectra of apo HS-9 and (D) the corresponding spectra of holo HS-9. (E) 15N-HSQC backbone 
spectra of apo HS-10 and (F) the corresponding spectra of holo HS-10. Each of these sequences, and especially HS-
10, displays an overall increase in chemical shift dispersion upon interaction with heme.  
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Figure 14. Structural characterization of the HSH proteins. (A) HSH-6, (B) HSH-7, (C) HSH-9, and (D) HSH-10 all 
exhibit the characteristic CD spectra of a random coil. Due to their high net charge and low hydrophobicity, these 
proteins cannot adopt the molten globular state required for heme binding.  
 
 
4.5 Implications for Future Design Procedures 
 The goal in modulating the hydrophobicity and net charge parameters in the 
aformentioned design procedure was to increase the solubility of the resulting sequences, and 
thereby enhance the success rate of the procedure as a whole. While that goal was not met in the 
case of all sequences in either the HS or HSH sequence libraries, the above results indicate that 
such an increase can nevertheless be achieved in future design efforts through a careful 
consideration of those parameters.  
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 With the sole exception of HSH-1, no positively charged sequence in either library could 
be successfully purified using the methods detailed in Section 4.3.1. Conversely, except for HS-8 
and HSH-8, neither of which could be overexpressed, every negatively charged sequence in both 
libraries could be purified with the same methods. These results agree with previous studies 
showing a strong positive correlation between solubility and negative surface charge count in 
natural proteins.78,79 This is most likely due to the differential hydration of the charge-carrying 
groups of positive and negatively charged amino acids,80 a fact that might account for the 
observed preference for negatively charged proteins throughout the proteome.81 Therefore, future 
versions of the protein design scheme described in Chapter 2 should see dramatically improved 
success rates if a negative net charge is imposed on all sequences. Further study is needed to 
determine the optimal range of net charge for functional sequences. 
  Figure 13 in Section 4.4.2 shows that the supercharged proteins HS7, HS9, and HS10 are 
molten globular in the apo state, and become more structured upon interaction with heme. This 
behavior indicates that the strong heme binding interaction sufficiently accounts for any 
nonspecific hydrophobic packing in the protein core.29 Most of the soluble HSH sequences were 
unable to bind heme and exhibited a preference for a random coil conformation (Figure 14). 
These two observations suggest that these proteins may be too highly charged and insufficiently 
hydrophobic to adopt the molten globular conformation requisite for heme binding.82 These 
results imply that supercharging alone may be sufficient to enhance the solubility of designed 
protein sequences, and that restricting the placement of hydrophobic residues might in fact be 
detrimental to proper folding. 
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Chapter 5: Engineering a Functional Di-Mangnese Enzyme 
 
5.1 Background 
5.1.1 The Oxygen Evolving Complex. In order to fulfill its potential as a robust, 
renewable, and clean energy source, solar irradiation must first be efficiently harvested and 
converted to a useable form. Natural photosynthetic organisms ‘solved’ the problem of 
converting solar energy into chemical energy about 2.5 billion years ago by using water as an 
electron source.83 Water is highly abundant and inexpensive, and as such is an ideal raw material 
for the formation of chemical fuels. Accordingly, one promising approach to solar fuel 
generation is to recreate and repurpose the essential water-splitting mechanism of natural 
photosynthesis using the tools of synthetic biology.6,84   
Natural photosynthetic water oxidation occurs in the oxygen-evolving complex (OEC), a 
metal center located in the protein complex Photosystem II. The OEC consists of four 
manganese atoms and one calcium atom arranged in a distorted cubane-like structure, with five 
oxygens serving as oxo bridges between the metals (Figure 15A).85 To be able to perform the 
four-electron oxidation of water, the OEC accumulates the necessary oxidizing equivalents via 
four successive oxidations by the chlorophyll center P680.
86,87 Crucially, the midpoint potential of 
the S3/S4 state couple of the OEC is above that of H2O/O2 at around 1.2V. The water splitting 
reaction then provides the electrons necessary to reset the OEC back to its most reduced state 
(S0), whereupon the cycle can begin again (Figure 15B).
87  
Decades of research into the structure and chemical mechanism of the OEC have 
uncovered various design principles for a photosynthetic water splitting catalyst.84 Chemists have 
subsequently implemented and greatly extended these principles by building simplified, 
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functional OEC model systems.88-90 Of particular interest is a family of oxo-bridged dinuclear 
manganese complexes, the first of which was synthesized by Brudvig in 1999.91 The success of 
these complexes indicates that a stable dimanganese metal center with reduction potential above 
that of the H2O/O2 couple and an open site for substrate water may be sufficient requirements for 
a model water oxidation catalyst.7 
 
Figure 15. Structure and function of the Oxygen Evolving Complex (OEC) of Photosystem II. (A) The geometry of 
the metal center of the OEC, which consists of four oxo-bridged manganese atoms and a single calcium atom in a 
distorted cubane-like arrangement. Figure adapted from the structure published by Umena et al.85 (B) The catalytic 
cycle of the OEC consists of four subsequent oxidations of the metal center via electron transfer to the P680 
chlorophyll molecule (S0 to S4), followed by a four-electron reduction of the metal center via water oxidation (S4 to 
S0).87 
 
 
5.1.2 Manganese Catalase. Manganese catalase is a binuclear manganese enzyme found 
in a wide range of organisms that catalyzes the disproportionation of hydrogen peroxide into 
water and dioxygen (Eq. 5):92  
(5)  2H2O2  ⟶  O2 +  2H2O 
Unlike the well-known heme-containing catalases, manganese catalase performs the above 
chemistry via two one-electron half-reactions wherein its metal center cycles between reduced 
Mn(II,II) and oxidized Mn(III,III) states (Eqs. 6 and 7):92  
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(6) H2O2 + {Mn2(III,III)} ⟶  O2 + {Mn2(II,II) + 2H
+} 
(7) H2O2 + {Mn2(II,II) + 2H
+} ⟶  2H2O + {Mn2(III,III)} 
 Manganese catalase isolated from L. plantarum contains a solvent-accessible oxo-bridged 
dimanganese complex at the center of a four-helix bundle domain (Figure 16).93 This type of 
binuclear metal center is relatively common in nature and found in enzymes as diverse as 
methane monooxygenase and ribonucleotide reductase.94 In manganese catalase, it is stable 
through multiple oxidation states, has openings for substrate H2O2, and can catalyze O-O bond 
formation.92 Parallels with the OEC have not gone unnoticed, as it has been investigated as a 
structural model for the S2 state of that complex.
95,96  
 
Figure 16. The structure of manganese catalase from L. plantarum with a single subunit highlighted in blue. This 
protein is homohexameric with subunits arranged into a shell surrounding a solvent-filled central cavity.92 Each 
subunit contains a four helix bundle domain housing a dimanganese active site. Figure adapted from crystal structure 
published by Whittaker et al.93 
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 Manganese catalase catalyzes a well-known reaction using a cofactor motif that has been 
thoroughly studied and is common across many enzymes. These characteristics make it an 
attractive target for de novo protein design efforts. A functional synthetic manganese catalase 
enzyme is an achievable goal, and its design will inform that of future polypeptide models of the 
OEC.  
5.1.3 The DF Series. The DF series of di-metal binding proteins, developed by DeGrado 
and coworkers early in the last decade, was a foundational achievement in protein design: the 
implantation of a common biological cofactor motif, the carboxylate-bridged dinuclear metal 
center, into a simple, robust four alpha helical bundle (Figure 17).97,98,99 This is the same 
catalytic cofactor found manganese catalase.94 As proof that this radical structural simplification 
is nevertheless enzymatically active, DeGrado has shown that the di-iron form of DF2 is a 
functional phenol oxidase enzyme.100 The binuclear active site of DF2 has been shown to 
accommodate many different metal ions including manganese,101 indicating that the DF 
backbone shows promise as a platform upon which to engineer other redox-active enzymes.  
 
Figure 17. Crystal structure of the di-manganese form of the homodimeric DF backbone.101 Metal-ligating residues 
are shown.  
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Figure 18. Comparison of the di-mangnaese active sites of (A) DF1101 and (B) Manganese Catalase.93 Both consist 
of oxo-bridged di-nuclear manganese clusters at the center of a four-helix bundle domain, ligated by three glutamate 
and two histidine residues.  
The DF backbone is structurally homologous to wild-type manganese catalase. Both 
proteins adopt an overall four-helix bundle motif and employ Glu and His side chains to ligate 
the metals in approximately the same carboxylate-bridged configuration (Figure 18). The di-
manganese form of DF1, however, fails to exhibit catalase activity likely due to an overall lack 
of flexibility, a lack of solvent accessibility at the metal site, and/or a failure to stabilize the 
oxidized form of manganese necessary for catalysis.102 
 
5.2 Re-Engineering an Artificial Di-Manganese Protein 
5.2.1 Topology Modification. To fashion a manganese catalase based on the 
homodimeric DF platform, the single chain monomeric protein (termed CDM2) was created by 
connecting two additional helices to the original DF2 monomer via two glycine-rich ‘strap’ 
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regions as shown in Figure 18. The single-chain has at least two distinct advantages over a 
homodimeric four-helix bundle topology. First, a modular single-chain structure can support 
non-symmetric mutations to the protein sequence. Such mutations are necessary for attachment 
to electrode surfaces or fine-tuned control of the second shell residues of the active site. Second, 
the use of flexible ‘strap’ regions rather than helical turns and the reversed orientation of helices 
1 and 4 encourage a greater overall flexibility in the protein backbone. By swapping these 
helices, the number of highly specific core packing interactions has been reduced in the bundle 
without deleteriously affecting the active site or the binary patterned sequence of each helix. 
Such a significant overhaul of the topology is only possible because the cofactor binding 
sequence is both symmetric and at the center of each of the four helices.  
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Figure 19. Sequence and topology representation of DF2, CDM2, and CDM13. Residues participating in metal 
ligation are highlighted in yellow. (A) The amino acid sequence of the DF2 homodimer with helices and loop 
sections indicated. (B) The amino acid sequence of CDM2, consisting of a monomer of DF2 connected via glycine-
rich ‘strap’ regions at each terminus to two additional helices. (C) CDM13 with mutations to enhance the solvent 
accessibility to the metal center (shown in red). (D) A schematic of the topology of DF2. The helix labels 
correspond to those in part A. (E) The topology of CDM2 and CDM13, which is distinct from that shown in part D. 
  
 56 
5.2.2 Active-Site Modification. A commonality of many computationally designed 
artificial proteins which bind cofactors or metals is an overly stabilized apo state with low 
solvent accessibility to the binding pocket, and the progression from multimeric to monomeric 
designs appears to exacerbate this problem. An open state competent for cofactor binding thus 
requires a significant degree of unfolding before binding can occur, and in some cases, 
destabilizing mutations must be introduced in order to expand the apoprotein conformational 
ensemble.103 Recently, Lombardi et al showed that the mutation of two key residues of di-ferric 
DF2 resulted in increased solvent accessibility via the partial destabilization of individual 
helices.104 Adapting this idea to CDM2, four mutations (L37G, L41G, L91G, and L95G) were 
made to the sequence (Figure 19 and Figure 20). This new sequence was termed CDM13.  
 
5.3 Materials and Methods 
5.3.1 Protein Preparation. Genes encoding CDM2 and CDM13 were purchased from 
Biomatik, Inc. (Cambridge, ON) with an N-terminal TEV cut site inserted between the BamHI 
and XhoI restriction sites of pET32a (+) (Novagen), which expresses proteins as His6-tagged 
thioredoxin fusions29. Protein purification was performed using the non-denaturing protocol as 
described in Section 4.3.1. Purified proteins were dialyzed into 20mM Ammonium Bicarbonate, 
2mM Glucose, pH 7.5 and lyophilized.  
5.3.2 Metal Complex Formation. Mn(II) binding by CDM-13 was monitored by circular 
dichroism (CD) spectroscopy. CD spectra were recorded on a JASCO J-810 spectropolarimeter 
in a 0.1cm quartz cuvette, using a bandwidth of 1nm and a scan speed of 50nm/min. Aliquots of 
a freshly prepared aqueous solution of MnCl2 were added to peptide solution (10 – 20 uM 
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protein, 10mM HEPES, pH 7.0), and samples were allowed to equilibrate for at least 30 minutes 
prior to data collection. 
5.3.3 Nuclear Magnetic Resonance Spectroscopy. NMR spectroscopy was performed 
as described in Section 4.3.2. Uniformly 15N-labeled lyophilized protein stock was suspended in 
50mM NaH2PO4, pH 6.5 with 10% D2O added before data collection. Experiments were 
performed at a four-helix bundle concentration of 100 µM. A freshly prepared aqueous stock 
solution of ZnCl was added to apo-CDM13 and samples were allowed to equilibrate for at least 
30 minutes before data collection. 
5.3.4 Electron Paramagnetic Resonance Spectroscopy. EPR Spectroscopy was 
performed in the laboratory of Prof. Gary Brudvig at Yale University, with the generous 
assistance of Dr. David Vinyard. EPR spectra were obtained on a Bruker ELEXYS E500 
spectrometer equipped with a SHQ resonator and an Oxford ESR-900 helium flow cryostat. 
Spectra were measured at 6.0-6.5 K using the following instrumental parameters: microwave 
frequency, 9.36 GHz; modulation frequency, 100 kHz; modulation amplitude, 19.5 G; 
microwave power, 20 mW. 
5.3.5 Catalytic Activity Measurement. The activity of CDM-13 was assayed by UV-Vis 
spectroscopy. Optical Spectra were collected with a Hewlett-Packard (New York, NY) 8452A 
Diode array spectrophotometer running the Olis (Bogart, CA) SpectralWorks software. A freshly 
prepared solution of H2O2 (1 – 20mM) was added to peptide solution (10uM in 100mM 
NaH2PO4, pH 7), and the mixture was immediately and thoroughly mixed. The 
disproportionation of H2O2 was monitored by the concomitant loss of absorbance at 240nm. The 
reaction was monitored over a 15-minute time course to determine the rate of H2O2 
disproportionation. 
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5.3.6 Stopped-Flow Analysis. The ‘burst phase’ kinetics of hydrogen peroxide 
disproportionation were analyzed in rapid stopped-flow mixing experiments by monitoring H2O2 
absorbance at 240nm using a Biologic (Lyon, France) SFM 300 stopped-flow mixer with a 
Biologic MOS 200 detector configured for single wavelength detection. Measurements were 
standardized with H2O2 solutions ranging from 0 – 25mM to yield a conversion factor of 0.021 
AU per millimolar H2O2. 50mM phosphate buffer pH 7.0 was mixed with H2O2 solution in the 
first mix, and both were subsequently combined with holo-CDM13 in the second mix. 
5.3.7 Aperometry. Amperometry was perfomed on CDM13 in the laboratory of Prof. 
Shelly Minteer at the Univerity of Utah with the kind help of Dr. Fabien Giroud. A three 
electrodes set-up was used for all the electrochemical experiments. Saturated calomel electrode 
and platinum mesh were used as the reference and the counter electrodes, respectively. 
Electrochemical tests were performed on basal plane HOPG electrodes as working electrodes. 
The electrodes were polished with 1 µm and 0.05 µm alumina powders thoroughly rinse with DI 
water, EtOH and sonicated for 5 min in EtOH. The electrodes were dried over a nitrogen flow. 
Then, 25 µL of a 2 mg/mL solution of CDM13-Mn were drop casted onto the graphite electrode 
and the protein film was allowed to dry in a desiccator under vacuum for 1 hour. Control 
experiments consisted of omitting the enzyme layer onto the graphite surface in presence of 
substrate. Blank experiments were performed without enzyme and without substrate. Cyclic 
voltammetry experiments were performed at 100 mV/s in 50 mM sodium phosphate, 100 mM 
sodium nitrate at pH = 7.0, in absence or presence of 5 mM H2O2 and only the second scan is 
shown. Chronoamperometry experiments were carried out at 650 mV vs. SCE. All experiments 
were realized inside a glove box under N2. During chronoamperometry experiments, dissolved 
 59 
O2 was monitored using an oxygen probe. The same probe was used previously to ascertain the 
solution was free of O2. 
 
 
 
5.4 Characterization of a Functional Manganese Catalase Mimic 
5.4.1 Metal-Binding Stoichiometry and Active-Site Characterization. As discussed in 
Section 5.2.1, the change in topology from DF2 to CDM2 was performed in part to destabilize 
the apo state of the protein and facilitate metal binding without the use of denaturants. However, 
even with the helix reversal, CDM2 does not detectably bind either Mn(II) or Co(II) after 16 
hour incubation times as observed optically, by isothermal titration calorimetry, or using circular 
dichroism (not shown). 
Figure 20. Increasing solvent accessibility at the dimetal active site. (A) Four leucine residues (red) block access to 
the active site of CDM2. (B) Those four positions (red) were mutated to glycine in CDM13.  
 
 
 To create the CDM13 sequence, four leucine residues blocking solvent access to the 
binding site in CDM2 were replaced by glycine (Fig 20B). As a result, CDM13 binds two 
equivalents of Mn2+ on a minutes time scale concomitant with a change in its alpha helical 
content (Figure 22, Left). As has been observed with other designed helical bundle proteins,105 
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apo-CDM13 appears to be partially molten globular as observed by NMR and the addition of 
two equivalents of Zn induces an ordering of the protein to a nativelike holoprotein state (Figure 
21). 
 
Figure 21. Changes to the CDM13 backbone upon interaction with metal atoms. 600MHz 15N-HSQC Spectra of 
150uM CDM13 in 50 mM NaH2PO4, pH 6.5 at 25C. (A) Apo CDM13 exhibits poor chemical shift dispersion and is 
likely molten globular. (B) Two atoms of Zn per bundle results in greater chemical shift dispersion. 
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Figure 22. (Left) Binding of Mn2+ to apo-CDM13. Circular dichroism (CD) spectra of 10uM CDM13 in 10uM ??, 
pH 7 at 25C. Representative CD spectra of CDM13. Stepwise addition of Mn2+ as MnCl2 results in a signal decrease 
at 220nm. Inset is a plot of the normalized CD signal at 220nm vs atoms of Mn2+ per bundle, exhibiting a break 
point at 2 Mn/Bundle. (Right) Full EPR spectra of holo-CDM13 at 6.0-6.5K after brief incubation with EDTA to 
minimize signal from unbound Mn2+. Inset is the detailed spectrum of a broad feature at g=1.98, exhibiting 
hyperfine peaks spaced 45 +/- 1 G apart. These hyperfine features are characteristic of an antiferromagnetically 
coupled Mn2+- Mn2+ dimer with ions spaced between 3.1-3.7A apart. 
 
 
 EPR analysis of the bound Mn(II) enables the confirmation of di-nuclear metal center 
assembly. In order to avoid overlapping signals from surface-bound Mn2+, 10mM EDTA was 
added to a mixture of 600μM CDM13 and 1mM MnCl2 in a quartz EPR tube, incubated for 20 s, 
a time chosen to allow chelation of free Mn2+ but not significant extraction of Mn2+ from the 
protein, and then quench cooled in liquid nitrogen.106 The EPR spectrum of holo-CDM13 
following this brief EDTA incubation is shown in Figure 22. The spectrum consists of a broad 
feature centered at g = 1.98 (peak-to-peak width ~560 G) overlaid with ~17 hyperfine features 
spaced 45 ± 1 G apart. This hyperfine-coupling constant is diagnostic for 55Mn in an 
antiferromagnetically coupled Mn2+-Mn2+ dimer.107,108 In accordance with previous studies at 
low temperature (≤15 K),108-110 the observed spectrum was assigned to the first excited state 
(S=1) of a weakly coupled Mn2+-Mn2+ dimer. While the Mn-Mn distance cannot be accurately 
determined without knowledge of the zero-field splitting interaction, a survey of model 
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complexes and Mn-containing enzymes containing similar weakly coupled Mn2+-Mn2+ dimers 
found a range of 3.1-3.7Å.110 
 
5.4.2 Catalytic Activity.  
Figure 23. Catalytic activity of CDM13. (Left) Michealis-Menten plot of steady-state H2O2 disproportionation 
catalyzed by holo CDM13. Inset is a representative trace of solution O2 concentration in the presence (orange) and 
absence (blue) of CDM13. (Right) Investigation of the ‘burst phase’ of CDM13-catalyzed H2O2 disproportionation. 
A typical time-course measurement of peroxide absorbance at 240nm during the reaction features a high-rate ‘burst 
phase’ followed by a steady-state disproportionation rate. Inset is a plot of the rate of this phase as a function of holo 
CDM13 concentration as determined by stopped flow analysis. 
 
 
 Assembled di-manganese CDM13 catalyzes the disproportionation of hydrogen peroxide 
under steady-state conditions with kcat and Km values of .084 ± .002 sec
-1 and 5.1 ± 0.5 mM, 
respectively, as monitored both by the disappearance of the peroxide absorbance at 240 nm 
(Figure 23, Left) and by the rate of production of oxygen (Figure 23, Left Inset). When the 
protein is mixed with hydrogen peroxide in a stopped-flow spectrophotometer, however, a 
significant catalytic burst is observed (Figure 23, Right), which is second order both in protein 
and hydrogen peroxide (Figure 23, Right Inset). The mechanism of this complex catalytic 
behavior is unclear. Natural manganese catalases exhibit similar behavior, forming EPR-
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observable trapped Mn3+/Mn4+ states that are inactive until re-reduced by an exogenous reducing 
agent.111 However, CDM13 frozen while undergoing steady state turnover is EPR silent, and 
during steady-state turnover with protein concentrations as high as 600 µM, no manganese 
intermediates can be detected optically. HPLC-MS analysis demonstrates that the protein does 
not change mass after catalyzing >106 turnovers, and protein re-isolated after catalysis using a 
desalting column exhibits the same burst behavior, within error, as was observed the first time. 
 
Figure 24. (Left) Representative chronoamperometric measurements and of bare basal plane electrodes (dashed 
line) and holo-CDM13 electrodes (solid line) upon successive addition of different concentration of H2O2. (Right) 
The calibration curve generated from the measurements on the left. Dashed lines represent fitting using the 
Michaelis-Menten equation.  
 
 
 Catalytic wave voltammetry performed on the di-manganese complex using a basal plane 
highly-oriented pyrolytic graphite (HOPG) electrode exhibits a significant rate of catalysis in the 
oxidative half reaction (Figure 24), but no observable current in the water-forming reductive half 
reaction. Amperometric analyses carried out with the working electrode set at +890 mV over a 
range of hydrogen peroxide concentrations (Figure 24B) demonstrate a maximal current density, 
Jmax, of 1184 ± 9 µA/cm
2 with a half-saturating substrate concentration of 27.7 ± 0.1 mM. This 
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current allows for the calculation of the lower limit of the kred for the reductive half reaction – 
assuming perfect monolayer formation with the helical bundle laying on its side, 9.25x1012 
CDM13 molecules will assemble per cm2. Dividing the observed current by this value gives a 
lower limit for kred of 400.0±0.2 s
-1. Given the overall kcat of 0.08 s
-1, Eq. 8112 can be used to 
demonstrate that the oxidative half reaction is completely rate-limiting, with an upper limit of 
0.08 s-1 for the rate.  
(8) 𝑘𝑐𝑎𝑡 =
𝑘𝑜𝑥𝑘𝑟𝑒𝑑
𝑘𝑜𝑥+𝑘𝑟𝑒𝑑
 
Experiments were also performed in an electrochemical cell containing an oxygen probe in order 
to quantify the production of O2 from the enzymatic reaction. The same trends observed in 
chronoamperometry can be drawn from the oxygen production assay in Figure 25. 
 
Figure 25. Calibration curves of oxygen production generated from successive injections of H2O2 during 
chronoamperometric measurements for bare electrode (empty square) and holo CDM13 (black square). The O2 
concentration was taken 10 seconds prior a new injection. The empty circles represent independent experiment 
where only [O2] was recorded with successive injection of the H2O2 solution. 
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5.4.3 Electrochemical Potentials of Metals. To determine the midpoint potential of 
CMD13, cyclic voltammetry experiments were performed in the potential window where the 
enzyme communicates with the electrode (Figure 26). In absence of oxygen, bare electrodes 
clearly do not show any signal from 0 to 1 V vs. SCE. Modified-basal plane graphite electrodes 
modified with the enzyme showed a redox peak, Epc (the cathodic peak potential) and Epa (the 
anodic peak potential) were found to be +670 and +940 mV vs. NHE, respectively. The scan 
rate-dependence of the peak areas predicts that 2.0 ± 0.1 electrons are transferred in each 
transition. 
 
Figure 26. Background-subtracted cyclic voltammogram of a CDM13-modified basal plane graphite electrode in 
50mM NaH2PO4, 100 mM nitrate, pH 7.0 at 100 mV/s in the absence of H2O2. Inset is the raw cyclic 
voltammogram of CDM13 overlaid with the signal from the unmodified electrode. 
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5.5 Implications for Future Artificial Manganese Enzymes 
 CDM13 exhibits a catalytic efficiency about 106-fold lower than that of wild-type 
manganese catalase. Another carboxylate-bridged binuclear manganese enzyme, arginase, has 
been shown to exhibit catalase activity even lower than that of CDM13.113 The great difference 
in catalytic activity between arginase and manganese catalase, despite their high degree of 
structural similarity, has been attributed to a difference in the Mn(II)-Mn(III) midpoint potential 
between manganese catalase and these structural mimics.114  
In studies with Manganese Superoxide Dismutase (MnSOD), Vance and Miller 
demonstrated that the optimal Em for MnSOD is midway between the potentials of the two half-
reactions it catalyzes, and any changes to this Em result in a decrease in overall catalytic 
activity.106 The two electron midpoint potential of CDM13, +805 mV is only slightly below that 
of the O2/H2O2 couple, +850 mV, but significantly higher than that of the H2O2/H2O couple. This 
provides an explanation for the low catalase activity displayed by CDM13 despite its ability to 
self-assemble a manganese catalase-like active site – the driving force for the reductive half 
reaction is too small. This further explains the large difference observed in the rates of the 
CDM13-catalyzed half reactions: the oxidative half-reaction has more than 0.8 V of driving force 
while the reductive half-reaction has less than 100 mV. 
 Finally, while the Mn2+/3+ couple reduction potential of CDM13 is too high to efficiently 
catalyze the dismutation of hydrogen peroxide, the Mn3+/4+ couple, assuming Mn4+ can be 
stabilized in CDM13, has a potential too high to be measured using an HOPG electrode. As 
mentioned earlier, such a high potential is necessary for any successful water oxidation catalyst 
because of the nature of the H2O/O2 midpoint potential.
18 Work is underway both to determine 
 67 
the Mn3+/4+ oxidation potentials of CDM13 and to test the Mn4+ complex for its ability to oxidize 
water. 
 
 68 
List of Publications 
 
Raju, G., Singh, S., Mutter, A. C., Everson, B. H., Cerda, J. F., & Koder, R. L. (2013). An 
extended scope synthesis of an artificial Safranin cofactor. Tetrahedron Letters 2013 53:1201–
1203 
 
Everson, B. H., French, C. A., Mutter, A. C., Nanda, V., & Koder, R. L. (2015). Hemoprotein 
design using minimal sequence information. (Manuscript In Preparation) 
 
Everson, B. H., Giroud, F. F., Vinyard, D., Bjerkefeldt, E., Minteer, S., Brudvig, G. & Koder, R. 
L. (2015). Engineering a de novo Manganese Catalase Enzyme. (Manuscript In Preparation) 
 
French, C. A., Everson, B. H., Mutter, A. C., Beck, S. E., Zhang, L., & Koder, R. L. (2015). 
Protein supercharging modulates cofactor binding by altering internal electric fields. (Manuscript 
In Preparation)
 69 
Works Cited 
 
 (1) Lawrence, M. S.; Phillips, K. J.; Liu, D. R. Journal of the American Chemical 
Society 2007, 129, 10110. 
 (2) Trevino, S. R.; Scholtz, J. M.; Pace, C. N. Journal of pharmaceutical sciences 
2008, 97, 4155. 
 (3) Hoffert, M. I.; Caldeira K Fau - Benford, G.; Benford G Fau - Criswell, D. R.; 
Criswell Dr Fau - Green, C.; Green C Fau - Herzog, H.; Herzog H Fau - Jain, A. K.; Jain Ak Fau 
- Kheshgi, H. S.; Kheshgi Hs Fau - Lackner, K. S.; Lackner Ks Fau - Lewis, J. S.; Lewis Js Fau - 
Lightfoot, H. D.; Lightfoot Hd Fau - Manheimer, W.; Manheimer W Fau - Mankins, J. C.; 
Mankins Jc Fau - Mauel, M. E.; Mauel Me Fau - Perkins, L. J.; Perkins Lj Fau - Schlesinger, M. 
E.; Schlesinger Me Fau - Volk, T.; Volk T Fau - Wigley, T. M. L.; Wigley, T. M. 
 (4) Blankenship, R. E.; Tiede Dm Fau - Barber, J.; Barber J Fau - Brudvig, G. W.; 
Brudvig Gw Fau - Fleming, G.; Fleming G Fau - Ghirardi, M.; Ghirardi M Fau - Gunner, M. R.; 
Gunner Mr Fau - Junge, W.; Junge W Fau - Kramer, D. M.; Kramer Dm Fau - Melis, A.; Melis 
A Fau - Moore, T. A.; Moore Ta Fau - Moser, C. C.; Moser Cc Fau - Nocera, D. G.; Nocera Dg 
Fau - Nozik, A. J.; Nozik Aj Fau - Ort, D. R.; Ort Dr Fau - Parson, W. W.; Parson Ww Fau - 
Prince, R. C.; Prince Rc Fau - Sayre, R. T.; Sayre, R. T. 
 (5) Gust, D.; Kramer, D.; Moore, A.; Moore, T. A.; Vermaas, W. MRS Bulletin 2008, 
33, 383. 
 (6) Alstrum-Acevedo, J. H.; Brennaman Mk Fau - Meyer, T. J.; Meyer, T. J. 
 (7) Cady, C. W.; Crabtree, R. H.; Brudvig, G. W. Coordination chemistry reviews 
2008, 252, 444. 
 (8) Coakley, K. M.; McGehee, M. D. Chemistry of Materials 2004, 16, 4533. 
 (9) Koder, R. L.; Dutton, P. L. 
 (10) Regan, L.; Degrado, W. F. Science 1988, 241, 976. 
 (11) Degrado, W. F.; Wasserman, Z. R.; Lear, J. D. Science 1989, 243, 622. 
 (12) Kuhlman, B.; Dantas, G.; Ireton, G. C.; Varani, G.; Stoddard, B. L.; Baker, D. 
Science 2003, 302, 1364. 
 (13) Choma, C. T.; Lear, J. D.; Nelson, M. J.; Dutton, P. L.; Robertson, D. E.; 
Degrado, W. F. J. Am. Chem. Soc. 1994, 116, 856. 
 (14) Robertson, D. E.; Farid, R. S.; Moser, C. C.; Urbauer, J. L.; Mulholland, S. E.; 
Pidikiti, R.; Lear, J. D.; Wand, A. J.; Degrado, W. F.; Dutton, P. L. Nature 1994, 368, 425. 
 (15) Huang, S. S.; Koder, R. L.; Lewis, M.; Wand, A. J.; Dutton, P. L. Proc. Natl. 
Acad. Sci. U. S. A. 2004, 101, 5536. 
 (16) Nanda, V.; Koder, R. L. Nature chemistry 2010, 2, 15. 
 (17) Purnick, P. E.; Weiss, R. Nature reviews. Molecular cell biology 2009, 10, 410. 
 (18) Rivalta, I.; Brudvig, G. W.; Batista, V. S. Current Opinion in Chemical Biology 
2012, 16, 11. 
 (19) Braun, P.; Goldberg, E.; Negron, C.; von Jan, M.; Xu, F.; Nanda, V.; Koder, R. 
L.; Noy, D. Proteins 2011, 79, 463. 
 (20) Marcus, R. A. The Journal of Chemical Physics 1956, 24, 966. 
 (21) Moser, C. C.; Keske, J. M.; Warncke, K.; Farid, R. S.; Dutton, P. L. Nature 1992, 
355, 796. 
 (22) Punnoose, A.; McConnell, L. A.; Liu, W.; Mutter, A. C.; Koder, R. L. PloS one 
2012, 7, e36065. 
 70 
 (23) DeGrado, W. F.; Regan, L.; Ho, S. P. Cold Spring Harbor symposia on 
quantitative biology 1987, 52, 521. 
 (24) Emberly, E. G.; Wingreen, N. S.; Tang, C. Proceedings of the National Academy 
of Sciences of the United States of America 2002, 99, 11163. 
 (25) Kamtekar, S.; Schiffer, J. M.; Xiong, H.; Babik, J. M.; Hecht, M. H. Science 
1993, 262, 1680. 
 (26) Chothia, C.; Gelfand, I.; Kister, A. Journal of molecular biology 1998, 278, 457. 
 (27) Regan, L.; Clarke, N. D. Biochemistry 1990, 29, 10878. 
 (28) Robertson, D. E.; Farid, R. S.; Moser, C. C.; Urbauer, J. L.; Mulholland, S. E.; 
Pidikiti, R.; Lear, J. D.; Wand, A. J.; DeGrado, W. F.; Dutton, P. L. Nature 1994, 368, 425. 
 (29) Koder, R. L.; Valentine, K. G.; Cerda, J.; Noy, D.; Smith, K. M.; Wand, A. J.; 
Dutton, P. L. Journal of the American Chemical Society 2006, 128, 14450. 
 (30) Negron, C.; Fufezan, C.; Koder, R. L. Proteins 2009, 74, 400. 
 (31) Pohl, F. M. Nature: New biology 1971, 234, 277. 
 (32) Engel, D. E.; DeGrado, W. F. J. Mol. Biol. 2004, 337, 1195. 
 (33) Chou, P. Y.; Fasman, G. D. Annu. Rev. Biochem. 1978, 47, 251. 
 (34) Mutter, A. C.; Norman, J. A.; Tiedemann, M. T.; Singh, S.; Sha, S.; Morsi, S.; 
Ahmed, I.; Stillman, M. J.; Koder, R. L. Journal of Structural Biology 2014, 185, 178. 
 (35) North, B.; Summa, C. M.; Ghirlanda, G.; DeGrado, W. F. Journal of molecular 
biology 2001, 311, 1081. 
 (36) Fufezan, C.; Zhang, J.; Gunner, M. R. Proteins 2008, 73, 690. 
 (37) Zhang, Z.; Huang, L.; Shulmeister, V. M.; Chi, Y. I.; Kim, K. K.; Hung, L. W.; 
Crofts, A. R.; Berry, E. A.; Kim, S. H. Nature 1998, 392, 677. 
 (38) Moser, C. C.; Anderson, J. L.; Dutton, P. L. Biochimica et biophysica acta 2010, 
1797, 1573. 
 (39) Lovell, S. C.; Word, J. M.; Richardson, J. S.; Richardson, D. C. Proteins 2000, 
40, 389. 
 (40) Koder, R. L.; Miller, A. F. Protein expression and purification 1998, 13, 53. 
 (41) Berry, E. A.; Trumpower, B. L. Anal. Biochem. 1987, 161, 1. 
 (42) Zhang, L.; Anderson, J. L. R.; Ahmed, I.; Norman, J. A.; Negron, C.; Mutter, A. 
C.; Dutton, P. L.; Koder, R. L. Biochemistry 2011, 50, 10254. 
 (43) Dutton, P. L. Methods in Enzymology 1978, 54, 411. 
 (44) Benesch, R. E.; Benesch, R. Science 1953, 118, 447. 
 (45) Blanchard, S. C.; Kim, H. D.; Gonzalez, R. L.; Puglisi, J. D.; Chu, S. Proceedings 
of the National Academy of Sciences of the United States of America 2004, 101, 12893. 
 (46) Roy, R.; Hohng, S.; Ha, T. Nature methods 2008, 5, 507. 
 (47) Andrade, M. A.; Chacon, P.; Merelo, J. J.; Moran, F. Protein Engineering 1993, 
6, 383. 
 (48) Delaglio, F.; Grzesiek, S.; Vuister, G.; Zhu, G.; Pfeifer, J.; Bax, A. J. Biomol. 
NMR 1995, 6, 277. 
 (49) Goddard, T. D.; Kneller, D. G.; The University of California, San Francisco: 
2007. 
 (50) Vuister, G. W.; Clore, G. M.; Gronenborn, A. M.; Powers, R.; Garrett, D. S.; 
Tschudin, R.; Bax, A. J. Magn. Reson. Ser. B 1993, 101, 210. 
 (51) Zhang, L.; Andersen, E. M.; Khajo, A.; Magliozzo, R. S.; Koder, R. L. 
Biochemistry 2013, 52, 447. 
 71 
 (52) McAllister, K. A.; Zou, H.; Cochran, F. V.; Bender, G. M.; Senes, A.; Fry, H. C.; 
Nanda, V.; Keenan, P. A.; Lear, J. D.; Saven, J. G.; Therien, M. J.; Blasie, J. K.; DeGrado, W. F. 
Journal of the American Chemical Society 2008, 130, 11921. 
 (53) Bender, G. M.; Lehmann, A.; Zou, H.; Cheng, H.; Fry, H. C.; Engel, D.; Therien, 
M. J.; Blasie, J. K.; Roder, H.; Saven, J. G.; DeGrado, W. F. Journal of the American Chemical 
Society 2007, 129, 10732. 
 (54) Calhoun, J. R.; Liu, W.; Spiegel, K.; Dal Peraro, M.; Klein, M. L.; Valentine, K. 
G.; Wand, A. J.; DeGrado, W. F. Structure 2008, 16, 210. 
 (55) Creamer, T. P.; Rose, G. D. Proceedings of the National Academy of Sciences of 
the United States of America 1992, 89, 5937. 
 (56) Koder, R. L.; Anderson, J. L.; Solomon, L. A.; Reddy, K. S.; Moser, C. C.; 
Dutton, P. L. Nature 2009, 458, 305. 
 (57) Huang, S. S.; Koder, R. L.; Lewis, M.; Wand, A. J.; Dutton, P. L. Proceedings of 
the National Academy of Sciences of the United States of America 2004, 101, 5536. 
 (58) Zhang, L.; Anderson, J. L.; Ahmed, I.; Norman, J. A.; Negron, C.; Mutter, A. C.; 
Dutton, P. L.; Koder, R. L. Biochemistry 2011, 50, 10254. 
 (59) Reedy, C. J.; Kennedy, M. L.; Gibney, B. R. Chemical communications 2003, 
570. 
 (60) Reddi, A. R.; Reedy, C. J.; Mui, S.; Gibney, B. R. Biochemistry 2007, 46, 291. 
 (61) Ghirlanda, G.; Osyczka, A.; Liu, W.; Antolovich, M.; Smith, K. M.; Dutton, P. L.; 
Wand, A. J.; DeGrado, W. F. Journal of the American Chemical Society 2004, 126, 8141. 
 (62) Discher, B. M.; Noy, D.; Strzalka, J.; Ye, S.; Moser, C. C.; Lear, J. D.; Blasie, J. 
K.; Dutton, P. L. Biochemistry 2005, 44, 12329. 
 (63) Wei, Y. N.; Liu, T.; Sazinsky, S. L.; Moffet, D. A.; Pelczer, I.; Hecht, M. H. 
Protein Science 2003, 12, 92. 
 (64) Griffey Rh Fau - Redfield, A. G.; Redfield Ag Fau - Loomis, R. E.; Loomis Re 
Fau - Dahlquist, F. W.; Dahlquist, F. W. 
 (65) Clore, G. M.; Kay, L. E.; Bax, A.; Gronenborn, A. M. Biochemistry 1991, 30, 12. 
 (66) Cavanagh, J.; Fairbrother, W. J.; Palmer III, A. G.; Skelton, N. J. Protein NMR 
spectroscopy: principles and practice; Academic Press, 1995. 
 (67) Cohen-Ofri, I.; van Gastel, M.; Grzyb, J.; Brandis, A.; Pinkas, I.; Lubitz, W.; Noy, 
D. Journal of the American Chemical Society 2011, 133, 9526. 
 (68) Zeng, X.-L.; Tang, K.; Zhou, N.; Zhou, M.; Hou, H. J. M.; Scheer, H.; Zhao, K.-
H.; Noy, D. Journal of the American Chemical Society 2013, 135, 13479. 
 (69) Rothlisberger, D.; Khersonsky, O.; Wollacott, A. M.; Jiang, L.; DeChancie, J.; 
Betker, J.; Gallaher, J. L.; Althoff, E. A.; Zanghellini, A.; Dym, O.; Albeck, S.; Houk, K. N.; 
Tawfik, D. S.; Baker, D. Nature 2008, 453, 190. 
 (70) Jiang, L.; Althoff, E. A.; Clemente, F. R.; Doyle, L.; Rothlisberger, D.; 
Zanghellini, A.; Gallaher, J. L.; Betker, J. L.; Tanaka, F.; Barbas, C. F., 3rd; Hilvert, D.; Houk, 
K. N.; Stoddard, B. L.; Baker, D. Science 2008, 319, 1387. 
 (71) Siegel, J. B.; Zanghellini, A.; Lovick, H. M.; Kiss, G.; Lambert, A. R.; St Clair, J. 
L.; Gallaher, J. L.; Hilvert, D.; Gelb, M. H.; Stoddard, B. L.; Houk, K. N.; Michael, F. E.; Baker, 
D. Science 2010, 329, 309. 
 (72) Fleishman, S. J.; Whitehead, T. A.; Ekiert, D. C.; Dreyfus, C.; Corn, J. E.; 
Strauch, E. M.; Wilson, I. A.; Baker, D. Science 2011, 332, 816. 
 72 
 (73) Richter, F.; Blomberg, R.; Khare, S. D.; Kiss, G.; Kuzin, A. P.; Smith, A. J.; 
Gallaher, J.; Pianowski, Z.; Helgeson, R. C.; Grjasnow, A.; Xiao, R.; Seetharaman, J.; Su, M.; 
Vorobiev, S.; Lew, S.; Forouhar, F.; Kornhaber, G. J.; Hunt, J. F.; Montelione, G. T.; Tong, L.; 
Houk, K. N.; Hilvert, D.; Baker, D. Journal of the American Chemical Society 2012, 134, 16197. 
 (74) Pey, A. L.; Rodriguez-Larrea, D.; Bomke, S.; Dammers, S.; Godoy-Ruiz, R.; 
Garcia-Mira, M. M.; Sanchez-Ruiz, J. M. Proteins 2008, 71, 165. 
 (75) Mao, A. H.; Crick, S. L.; Vitalis, A.; Chicoine, C. L.; Pappu, R. V. Proceedings of 
the National Academy of Sciences of the United States of America 2010, 107, 8183. 
 (76) Dill, K. A. Biochemistry 1990, 29, 7133. 
 (77) Watters, A. L.; Deka, P.; Corrent, C.; Callender, D.; Varani, G.; Sosnick, T.; 
Baker, D. Cell 2007, 128, 613. 
 (78) Trevino, S. R.; Scholtz, J. M.; Pace, C. N. Journal of molecular biology 2007, 
366, 449. 
 (79) Kramer, R. M.; Shende, V. R.; Motl, N.; Pace, C. N.; Scholtz, J. M. Biophysical 
journal 2012, 102, 1907. 
 (80) Collins, K. D. Biophysical journal 1997, 72, 65. 
 (81) Xu, Y.; Wang, H.; Nussinov, R.; Ma, B. Proteomics 2013, 13, 1339. 
 (82) Müller-Späth, S.; Soranno, A.; Hirschfeld, V.; Hofmann, H.; Rüegger, S.; 
Reymond, L.; Nettels, D.; Schuler, B. Proceedings of the National Academy of Sciences 2010, 
107, 14609. 
 (83) Raymond, J.; Blankenship, R. E. Coordination chemistry reviews 2008, 252, 377. 
 (84) Lubitz, W.; Reijerse, E. J.; Messinger, J. Energy & Environmental Science 2008, 
1, 15. 
 (85) Umena, Y.; Kawakami, K.; Shen, J.-R.; Kamiya, N. Nature 2011, 473, 55. 
 (86) McEvoy, J. P.; Brudvig, G. W. 
 (87) Kok, B.; Forbush, B.; McGloin, M. Photochemistry and photobiology 1970, 11, 
457. 
 (88) Gersten, S. W.; Samuels, G. J.; Meyer, T. J. Journal of the American Chemical 
Society 1982, 104, 4029. 
 (89) Rotzinger, F. P.; Munavalli, S.; Comte, P.; Hurst, J. K.; Graetzel, M.; Pern, F. J.; 
Frank, A. J. Journal of the American Chemical Society 1987, 109, 6619. 
 (90) Sens, C.; Romero, I.; Rodríguez, M.; Llobet, A.; Parella, T.; Benet-Buchholz, J. 
Journal of the American Chemical Society 2004, 126, 7798. 
 (91) Limburg, J.; Vrettos, J. S.; Liable-Sands, L. M.; Rheingold, A. L.; Crabtree, R. 
H.; Brudvig, G. W. Science 1999, 283, 1524. 
 (92) Whittaker, J. W. Archives of biochemistry and biophysics 2012, 525, 111. 
 (93) Barynin, V. V.; Whittaker, M. M.; Antonyuk, S. V.; Lamzin, V. S.; Harrison, P. 
M.; Artymiuk, P. J.; Whittaker, J. W. Structure 2001, 9, 725. 
 (94) Calhoun, J. R.; Nastri, F.; Maglio, O.; Pavone, V.; Lombardi, A.; DeGrado, W. F. 
Biopolymers 2005, 80, 264. 
 (95) Sproviero, E. M.; McEvoy, J. P.; Gascón, J. A.; Brudvig, G. W.; Batista, V. S. 
Photosynthesis research 2008, 97, 91. 
 (96) Stemmler, T. L.; Sossong, T. M.; Goldstein, J. I.; Ash, D. E.; Elgren, T. E.; Kurtz, 
D. M.; Penner-Hahn, J. E. Biochemistry 1997, 36, 9847. 
 73 
 (97) Lombardi, A.; Summa, C. M.; Geremia, S.; Randaccio, L.; Pavone, V.; DeGrado, 
W. F. Proceedings of the National Academy of Sciences of the United States of America 2000, 
97, 6298. 
 (98) Di Costanzo, L.; Wade, H.; Geremia, S.; Randaccio, L.; Pavone, V.; DeGrado, W. 
F.; Lombardi, A. Journal of the American Chemical Society 2001, 123, 12749. 
 (99) Marsh, E. N. G.; DeGrado, W. F. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 5150. 
 (100) Faiella, M.; Andreozzi, C.; de Rosales, R. T. M.; Pavone, V.; Maglio, O.; Nastri, 
F.; DeGrado, W. F.; Lombardi, A. Nature chemical biology 2009, 5. 
 (101) Geremia, S.; Di Costanzo, L.; Randaccio, L.; Engel, D. E.; Lombardi, A.; Nastri, 
F.; DeGrado, W. F. Journal of the American Chemical Society 2005, 127, 17266. 
 (102) Spiegel, K.; De Grado, W. F.; Klein, M. L. Proteins 2006, 65, 317. 
 (103) Maglio, O.; Nastri, F.; Pavone, V.; Lombardi, A.; DeGrado, W. F. Proc. Natl. 
Acad. Sci. U. S. A. 2003, 100, 3772. 
 (104) Torres Martin de Rosales, R.; Faiella, M.; Farquhar, E.; Que, L., Jr.; Andreozzi, 
C.; Pavone, V.; Maglio, O.; Nastri, F.; Lombardi, A. Journal of biological inorganic chemistry : 
JBIC : a publication of the Society of Biological Inorganic Chemistry 2010, 15, 717. 
 (105) Koder, R. L.; Valentine, K. G.; Cerda, J. F.; Noy, D.; Smith, K. M.; Wand, A. J.; 
Dutton, P. L. J. Am. Chem. Soc. 2006, 128, 14450. 
 (106) Vance, C. K.; Miller, A. F. J. Am. Chem. Soc. 1998, 120, 461. 
 (107) Hudson, A.; de G. Kennedy, M. J. Inorganic and Nuclear Chemistry Letters 1971, 
7, 333. 
 (108) Mathur, P.; Dismukes, G. C. Journal of the American Chemical Society 1983, 
105, 7093. 
 (109) Hingorani, K.; Pace, R.; Whitney, S.; Murray, J. W.; Smith, P.; Cheah, M. H.; 
Wydrzynski, T.; Hillier, W. Biochimica et Biophysica Acta (BBA) - Bioenergetics 2014, In press. 
 (110) Khangulov, S. V.; Pessiki, P. J.; Barynin, V. V.; Ash, D. E.; Dismukes, G. C. 
Biochemistry 1995, 34, 2015. 
 (111) Wu, A. J.; Penner-Hahn, J. E.; Pecoraro, V. L. Chem. Rev. 2004, 104, 903. 
 (112) Cleland, W. W. In Investigation of rates and mechanisms of reaction; Bernasconi, 
C. F., Ed.; John Wiley and Sons: New York, N.Y., 1986; Vol. VI, p 791. 
 (113) Sossong, T. M.; Khangulov, S. V.; Cavalli, R. C.; Soprano, D. R.; Dismukes, G. 
C.; Ash, D. E. J. Biol. Inorg. Chem. 1997, 2, 433. 
 (114) Dismukes, G. C. Chemical reviews 1996, 96, 2909. 
 
